Effect of Carbon Monoxide-Releasing Molecule-3 on the Severity of Endothelial Dysfunction Due to Elevation of Hydrostatic Pressure in an In Vitro Model of Compartment Syndrome by Taylor, Michel A.
Western University 
Scholarship@Western 
Electronic Thesis and Dissertation Repository 
10-23-2017 6:00 PM 
Effect of Carbon Monoxide-Releasing Molecule-3 on the Severity 
of Endothelial Dysfunction Due to Elevation of Hydrostatic 
Pressure in an In Vitro Model of Compartment Syndrome 
Michel A. Taylor 
The University of Western Ontario 
Supervisor 
Dr. AbdelRahmann Lawendy 
The University of Western Ontario 
Graduate Program in Surgery 
A thesis submitted in partial fulfillment of the requirements for the degree in Master of Science 
© Michel A. Taylor 2017 
Follow this and additional works at: https://ir.lib.uwo.ca/etd 
 Part of the Orthopedics Commons 
Recommended Citation 
Taylor, Michel A., "Effect of Carbon Monoxide-Releasing Molecule-3 on the Severity of Endothelial 
Dysfunction Due to Elevation of Hydrostatic Pressure in an In Vitro Model of Compartment Syndrome" 
(2017). Electronic Thesis and Dissertation Repository. 5007. 
https://ir.lib.uwo.ca/etd/5007 
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted 
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of 
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca. 
	 ii 
ABSTRACT 
 
Compartment syndrome (CS) is a surgical emergency caused by elevated pressure 
within a closed osseofascial compartment. It leads to microvascular dysfunction, limiting 
oxygen and nutrient delivery, gas exchange, resulting in cellular anoxia, muscle necrosis 
and cell death.  
Currently, the only effective treatment is surgical fasciotomy. Recently, carbon 
monoxide (CO) delivered via carbon monoxide releasing molecule-3 (CORM-3) has been 
shown to improve microvascular perfusion and convey anti-inflammatory benefits in 
animal models of CS.  
The contribution of elevated hydrostatic pressure (EHP) to the pathophysiology of 
CS was examined in an in vitro model of CS. We found that EHP led to increased 
oxidative stress, apoptosis and structural changes within the human vascular endothelial 
cells; application of CORM-3 diminished the magnitude of these detrimental responses. 
The data suggest that CORM-3 provides beneficial effects by preventing endothelial 
activation while preserving endothelial integrity, making CORM-3 an excellent potential 
adjunct pharmacological therapeutic in CS. 
 
 
Keywords: compartment syndrome, elevated hydrostatic pressure, human vascular 
endothelial cells, carbon monoxide, CORM-3, endothelial integrity, 
oxidative stress, apoptosis, inflammation. 
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CHAPTER 1.  INTRODUCTION AND HISTORICAL REVIEW 
 
 
1.1 COMPARTMENT SYNDROME 
Compartment syndrome (CS) is a true medical and surgical emergency, with 
potential devastating consequences, caused by an elevated pressure within a closed 
osseofascial compartment (Mubarak, Owen et al. 1978, Rorabeck and Clarke 1978, 
Matsen, Winquist et al. 1980, Hartsock, O'Farrell et al. 1998). The intercompartmental 
fascia is unyielding and as such, individual compartments have limited ability to expand; 
this makes them vulnerable to small increases in intracompartmental pressure (ICP) or 
decreases in volume.  
The increase in pressure within the compartment leads to microvascular 
dysfunction and compromise, thereby creating an ischemic environment within the 
compartment. This then limits oxygen and nutrient delivery, as well as gas exchange, 
resulting in cellular anoxia, muscle necrosis and eventual cell death (Sheridan and 
Matsen 1975, Whitesides, Haney et al. 1975, Mubarak, Owen et al. 1978, Rorabeck and 
Clarke 1978, Matsen, Winquist et al. 1980). Interestingly, the ischemic environment 
occurs in the presence of patent vasculature. Acute CS can result in severe functional 
impairment, permanent pain, disability, limb loss, and even death. CS may occur acutely, 
following both high- and low-energy trauma, but can also present as a chronic 
intermittent condition, such as exertional compartment syndrome, which is most 
commonly seen in the athletic or military populations.  
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Various types of injuries and medical conditions have been associated with the 
development of acute CS such as fractures, contusions, burns, tight casts & dressings, 
blast injuries, gunshot wounds, crush injuries, diabetes, bleeding disorders (Hope and 
McQueen 2004), statin medications (Chautems, Irmay et al. 1997, Jose, Viswanathan et 
al. 2004), various infections (Schnall, Holtom et al. 1994) and placing patients in 
prolonged lithotomy positions for surgical procedures (Goldsmith and McCallum 1996, 
Mathews, Perry et al. 2001). CS has been described in the arm, forearm, hand, buttock, 
thigh, lower leg, foot, abdomen, thorax and even the orbit (Greene and Louis 1983, 
Bonutti and Bell 1986, Brumback 1990, Kym and Worsing 1990, Frink, Hildebrand et al. 
2010).  
 
1.1.1 Brief Historical Review of CS 
 In 1881, the German surgeon Richard von Volkmann first described the clinical 
sequelae of CS following traumatic supracondylar distal humerus fractures. He attributed 
the devastating clinical outcome to the interruption of arterial blood supply but did not 
specify the cause (von Volkmann 1881). This observation by von Volkmann was further 
substantiated by Leser in 1884 who, by applying a tight bandage to the limbs of animals, 
noted time dependent necrotic changes in the muscle, as well as venous congestion and 
swelling (Leser 1884). In 1906, Hildebrand drew attention to the role of nerve 
involvement in the pathophysiology of ischemic contractures after replicating the 
experimental design of Leser, and coined the term ‘Volkmann’s contracture’ to refer to 
the clinical sequelae following supracondylar distal humerus fractures (Hildebrand 1906). 
In 1914, Murphy changed the narrative, and instead of speaking of arterial injuries and 
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nerve involvement as underlying causes of ischemic contractures, he drew attention to 
venous obstruction as the driving force behind CS. Although we now know that venous 
obstruction is not a major underlying contributor of CS, Murphy importantly drew 
attention to the idea that 1. elevated ICP was a main driving force in the pathophysiology, 
that 2. arterial pulses were maintained during the process and finally that 3. by splitting 
the underlying deep fascia, the “obstruction” could be relieved (Murphy 1914). Until this 
point, treatments had been aimed towards the complications of CS and ischemia, such as 
fibrosis and contractures (Rowlands and Lond 1905).  
In 1926, through a series of elegant ischemia-reperfusion experiments using the 
limbs of dogs, Jepson noted that elapsed time as well as increased pressure was a direct 
causal factor in the pathogenesis of ischemic contractures. More importantly, he also 
showed that by surgically decompressing the involved compartment, the function of the 
limb could be restored (Jepson 1926).  
The next significant contribution was likely from the work of Griffiths (1940), 
and although he mistakenly argued (for the better part of two decades) that arterial spasm 
was the root cause of the resulting ischemic contracture, his research contributed 
significantly to our understanding and recognition of early clinical signs and symptoms of 
CS, such as pain out of proportion, pain with passive extension and ‘puffiness’, which are 
still widely taught to this day (Griffiths 1940).  
The next main contribution to our understanding of CS came with the bombing 
raids known as the London Blitz in the early 1940s. Patients with crushed extremities 
would be taken to hospital, and a relatively stable clinical condition would quickly 
deteriorate into systemic decompensation, multi-organ failure and eventual death. The 
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condition became known as “crush syndrome” (Bywaters, Delory et al. 1941). This 
highlighted the importance of ischemia-reperfusion in the pathogenesis of CS, rather than 
strictly speaking of venous congestion and elevated ICP.  
In 1975, Matsen delivered his unified theory of CS by combining all the relevant 
data available to that point. The important aspects of his theory stated that CS was not 
restricted only to the upper extremity, that elevated pressure was a critical feature of the 
condition and finally that relieving the ICP via surgical fasciotomy was critical to avoid 
the devastating sequelae (Sheridan and Matsen 1975). The importance of Matsen’s 
contribution cannot be overstated, as he shifted the discourse from understanding the 
underlying pathophysiology to better ways of diagnosing and treating acute CS.  
 
1.1.2 Diagnosis of CS 
The early identification, diagnosis and treatment of CS are critical in order to 
relieve ICP, prevent ongoing tissue anoxia, necrosis and optimize patient outcome, as 
well as prevent long-term disability. The diagnosis of CS is primarily a clinical one, 
which, in certain circumstances may be supplemented by direct ICP measurements. 
Understanding patient risk factors and the early identification of patient clinical signs and 
symptoms are paramount in the diagnosis and appropriate management of CS. Risk 
factors include male gender, age under 35, tibia fracture, high energy forearm fractures, 
high energy long bone fracture and comminuted fractures. 
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1.1.2.1 Clinical Diagnosis 
There are several signs and symptoms that have traditionally been associated with 
acute CS. They appear in a stepwise fashion, although the timing can vary significantly 
from patient to patient and injury to injury (Myers 2000, Elliott and Johnstone 2003, 
Olson and Glasgow 2005, Shadgan, Menon et al. 2008). For this reason, the importance 
of serial and thorough clinical evaluations of all patients at risk of developing CS cannot 
be overstated; currently, this is considered the standard of care in the management of CS. 
The presence of symptoms should not only alert clinicians to the diagnosis of an acute 
CS, but also, unfortunately, likely suggests an advanced stage of disease.  
The first signs and symptoms associated with CS are usually pain out of 
proportion to the apparent injury, and pain with passive stretch of the involved muscle 
compartment (Whitesides and Heckman 1996). The sensitivity and specificity of these 
clinical findings has been found to be between 13-19% and 97% respectively (Whitesides 
and Heckman 1996, Ulmer 2002). Other symptoms associated with CS include tense and 
painful muscle compartments, a persistent deep ache or burning pain, paresthesia or 
increasing analgesia requirement, with the last of these being an especially important 
finding in the pre-verbal pediatric population (Bae, Kadiyala et al. 2001). 
 
1.1.2.2 Physical Examination 
The first description of the clinical criteria for the diagnosis of CS was provided 
by Griffiths in 1940. Griffiths established the original “four Ps”: pain out of proportion 
and pain on passive stretch, paraesthesia, paralysis and ‘puffiness’ (Griffiths 1940). 
Eventually, pallor and pulselessness were also added to the physical signs of CS (Cascio, 
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Wilckens et al. 2005). Unfortunately, some of these physical exam findings, such as 
paresthesia and paralysis, are considered late findings of established CS (McQueen, 
Christie et al. 1996), and often signify that irreversible vascular, muscular and 
neurological injury have likely already occurred (Matsen and Clawson 1975, Ulmer 
2002). Although pulselessness was traditionally taught as one of the “5 Ps” in the clinical 
diagnosis of CS, the absence of a pulse is no longer considered a feature of CS (Manjoo, 
Sanders et al. 2010) and the presence of a pulse certainly does not rule out a diagnosis of 
CS. Failing to identify CS and obtain a timely diagnosis is the greatest cause of adverse 
clinical outcomes (Matsen and Clawson 1975, Rorabeck 1984, McQueen, Christie et al. 
1996, Mars and Hadley 1998). In addition, missed CS is one of the most frequently 
argued cases in the field of medico-legal litigation, and is associated with frequent and 
significant judgements in the favour of the plaintiff (Bhattacharyya and Vrahas 2004). 
 
1.1.2.3 Objective Compartment Pressure Monitoring 
The direct measurement of ICP when attempting to diagnose CS, provided the 
proper technique is used, is a valuable tool in the clinician’s armamentarium (Hargens 
and Ballard 1995). Various measurement techniques have been described, such as needle 
manometer, wick catheter, slit catheter and electronic transducer-tipped catheters 
(Hargens and Ballard 1995). In order to capture the peak ICP value, measurements 
should be taken at the level of the fracture, as well as additional sites up to 5 cm proximal 
and distal to the injury (Heckman, Whitesides et al. 1994). In addition, pressures should 
also be measured in the other compartments of the affected limb, to ensure that a CS is 
not missed. The electronic transducer-tipped systems have been found to be the most 
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accurate, as they do not rely on limb position or the height of the transducer. All direct 
compartment pressure measurement devices have their own specific technical steps, are 
user dependent, have their own advantages and disadvantages, and are not immune to 
false negatives (Lawendy and Sanders 2010).  Although some authors have argued that 
all patients (especially young men) presenting with tibial diaphyseal fractures, high 
energy fractures of the tibial metaphysis, soft tissue injuries or in patients with an 
accompanied bleeding diathesis should undergo objective compartment pressure 
monitoring (McQueen, Gaston et al. 2000), this is currently not the usual practice.  There 
are, however, several indications for using ICP monitors. These include unconscious 
patients, pediatric patients, pre-verbal and non-verbal patients, patients with equivocal 
signs and symptoms, patients with associated neurological injuries, or in a polytrauma 
scenario (Whitesides, Haney et al. 1975, Gelberman, Garfin et al. 1981, Hargens, 
Schmidt et al. 1981, Hargens, Akeson et al. 1989). In these cases, continuous 
compartment pressure monitoring may help confirm clinical findings, decrease the delay 
to fasciotomy and may, as a result, decrease the long-term complications of the disorder 
(McQueen, Christie et al. 1996).  
 
1.1.3 Consequences of Missed CS 
The early identification and diagnosis of acute CS is critical to its successful 
management, and will maximize the chances of a positive clinical outcome. The inability 
to obtain a timely diagnosis is the most common cause of adverse clinical outcomes 
(Matsen and Clawson 1975, Rorabeck 1984, McQueen, Christie et al. 1996, Mars and 
Hadley 1998). A missed or late diagnosis of acute CS can lead to serious complications, 
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such as muscle infarction, muscle and joint contractures, secondary joint and soft tissue 
deformities, limb weakness and neurologic dysfunction (Whitesides and Heckman 1996). 
Less common, but nonetheless important complications of missed CS include infection, 
gram-negative sepsis, amputation and end-organ involvement (Whitesides and Heckman 
1996). The end result of missed CS is often irreversible myoneural ischemia leading to 
various degrees of permanent neuromuscular deficits and dysfunction. 
The severity of the clinical outcome and dysfunction depends on the amount of 
tissue affected, and can range from mild weakness and sensory changes to severe 
ischemic contractures and limb dysfunction. When a sufficiently large amount of muscle 
tissue is involved (often combined with a weakened and compromised immune system), 
CS can lead to severe systemic complications such as crush syndrome, rhabdomyolysis, 
renal failure (secondary to myoglobinuria) and systemic shock (Sanghavi, Aneman et al. 
2006, West 2007). 
A missed or late diagnosis can be the result of clinical inexperience, a lack of 
suspicion, or a confusing clinical presentation (McQueen, Christie et al. 1996). These 
situations can occur when patients present with altered pain perception, altered level of 
consciousness, regional anesthesia, patient-controlled analgesia and nerve injury; all are 
known risk factors for late diagnosis (Mubarak and Wilton 1997, Harrington, Bunola et 
al. 2000). 
 
 
	 9 
1.2 THERAPEUTIC APPROACHES TO CS 
The therapeutic goals of treating acute CS are to minimize chronic, long lasting 
injury and dysfunction of the involved limb, by accurately and efficiently diagnosing the 
condition and restoring the compartments microcirculatory environment. This is done in 
order to avoid the devastating consequences of myonecrosis, ischemic contracture and 
limb dysfunction. Non-operative techniques and adjuncts have been studied in various 
animal models and human case series with limited success. These nonoperative 
treatments remain unproven, making surgical decompression through fasciotomy of all 
involved compartments the only gold standard therapy for acute established CS, provided 
it is carried out within 6-8 hours of CS onset (Eaton and Green 1972, Matsen, Winquist et 
al. 1980, Rorabeck 1984, McQueen, Hajducka et al. 1996, Lawendy and Sanders 2010). 
 
1.2.1 Fasciotomy 
Fasciotomy, as a technique for the surgical treatment of patients with impeding 
Volkmann’s contracture, was first described in 1911 by Bardenheuer (Bardenheuer 1911) 
although at the time, he used the term ‘aponeurectomy’. Eventually, Murphy in 1914 
suggested early surgical fasciotomy for the treatment of increased pressure within a 
fascial-enclosed space due to hemorrhage and edema in order to prevent paralysis and 
contractures (Murphy 1914). The concept of surgical fasciotomy, as described by 
Murphy, is the mainstay for the treatment of CS today. The first detailed record of the 
actual operative technique was provided by Benjamin (Benjamin 1957), describing the 
surgical approach to the forearm. Fasciotomy is urgently performed to normalize 
compartment pressures, in the hope of restoring normal perfusion to the affected tissues, 
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halting the inflammatory process and ultimately preventing the devastating clinical 
sequelae. After 6-8 hours, the risk of permanent tissue damage increases exponentially. 
Once muscle and tissue necrosis has occurred, surgical fasciotomy is contraindicated as it 
increases the risk of infection significantly. Adding to the complexity of this clinical 
presentation, one often does not know the exact time of injury or the subsequent events 
that have led to the patient’s current state, making decision making difficult. Therefore, 
frequent serial clinical examinations and reassessment are extremely important. 
Fasciotomy releases the involved compartment(s), allowing soft tissues to swell 
and expand, thus allowing for an increased compartmental volume while decreasing the 
ICP. Following decompression, surgical wounds are usually left open for 48-72 hours 
prior to skin closure, which is often accompanied by split thickness skin grafting 
(Lawendy and Sanders 2010). 
 
1.2.1.1 Threshold for Decompression 
Considering the significant cost of missing a CS, some authors have expanded the 
indications of using ICP monitoring to include all traumas and fractures with a high risk 
of CS (McQueen, Gaston et al. 2000). To complicate matters further, various ICP 
thresholds have been proposed, at which fasciotomy should be performed, although there 
is currently no clear consensus. Protocols have included absolute values of 30 mmHg, 40 
mmHg and 45 mmHg (Mubarak, Owen et al. 1978, Matsen, Winquist et al. 1980, 
Schwartz, Brumback et al. 1989) while others, rather than considering the absolute ICP of 
a compartment, have used the difference between a compartment’s ICP and the patient’s 
diastolic pressure (∆P), with 20 to 30 mmHg being considered an indication for 
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fasciotomy (Whitesides, Haney et al. 1975). Most trauma surgeons prefer using this ∆P as 
a cut-off measure to perform fasciotomy rather than using an absolute ICP threshold, as 
this becomes more useful in hypotensive trauma patients leading to a lower overall 
fasciotomy rate when compared to an absolute pressure threshold (Matsen, Winquist et 
al. 1980, McQueen, Hajducka et al. 1996). A recent study by Whitney et al (2014) looked 
at false positive rates of CS diagnosis based on one-time ICP measurements alone. When 
using a ∆P threshold of 30 and 20 mmHg they reported a false positive rate of 35% and 
24% respectively (Whitney, O'Toole et al. 2014). 
 
1.2.1.2 Fasciotomy Techniques 
Surgical fasciotomy techniques have been well described for the upper and lower 
extremities as well as the trunk (McQueen, Gaston et al. 2000). Fasciotomies for CS of 
the lower leg (80% of all cases), forearm and hand are among the most commonly 
performed. 
 
1.2.1.2.1 Fasciotomy in the Lower Leg 
The lower leg is divided into 4 osseofascial compartments: anterior, lateral, 
posterior superficial and posterior deep (Gray 2000) (Figure 1.1). The anterior 
compartment is the most commonly affected in CS (Rorabeck and Macnab 1976). There 
are two commonly described techniques for the surgical decompression of the lower leg: 
the two-incision and single-incision, four-compartment fasciotomy.  
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Figure 1.1. Anatomy and compartments of the lower leg. The lower leg is 
comprised of the tibia and fibula, with interconnecting fascial 
planes separating the various muscles into anterior, lateral, 
superficial posterior and deep posterior compartments. 
 Reproduced with permission from Lawendy and Sanders (2010). 
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Some surgeons will routinely employ a two-incision (medial and anterolateral) 
technique, while others perform a single anterolateral approach in patients with CS in 
order to decompress both the anterior and lateral compartments, and then reassess the 
remaining compartments with ICP monitors before releasing the posterior superficial and 
posterior deep compartments (Tornetta, Puskas et al. 2016). Better visualization of tissue 
planes, neurovascular structures and ability to assess the conditions of soft tissues have 
been described as reasons to preferentially perform a two-incision approach (Lawendy 
and Sanders 2010). However, both single-incision and two-incision approaches have been 
shown to adequately decompress all 4 lower leg compartments (Neal, Henebry et al. 
2016).  
 
1.2.1.2.2 Fasciotomy in the Forearm 
The forearm is made up of the volar compartment, the extensor compartment and 
the mobile wad. The flexor compartment is divided into superficial, middle and deep 
muscle layers. The dorsal extensor compartment contains superficial and deep layers 
(Gray 2000).  
A curvilinear incision is made, extending from proximal and medial aspect to the 
elbow flexion crease, which then crosses the flexor surface of the elbow at an oblique 
angle. This is then followed by moving lateral to the midline, allowing for an extensile 
approach and the ability to release the carpal tunnel if needed. Medial and lateral flaps are 
elevated; the lateral antebrachial cutaneous nerve is found and protected. The lacertus 
fibrosis, the most proximal tether, is also released. The fascia overlying the superficial 
volar compartment is then incised, as well as the mobile wad laterally. The interval 
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between the flexor carpi ulnaris and the flexor digitorum superficialis is exploited to 
reveal the deep volar compartment which can then also be released (Gray 2000).  
 
1.2.1.2.3 Fasciotomy in the Hand 
The hand is divided into ten compartments; these include the thenar, hypothenar, 
adductor pollicis, four dorsal interossei and three volar interossei compartments (Gray 
2000). 
Two longitudinal incisions are centered over the index and ring fingers on the 
dorsum of the hand. Soft tissues are bluntly dissected on either side of the metacarpals, 
incising through the dorsal interossei muscle fascia. If the thenar and hypothenar 
compartments need to be released, two separate incisions are made on the volar radial 
aspect of the thumb and the volar ulnar aspect of the 5th digit, respectively. The carpal 
tunnel can be released through a 4cm longitudinal incision, in line with the ring finger, 
with the proximal extent being the flexor crease of the wrist. The transverse carpal 
ligament is then released under direct visualization (Kalyani, Fisher et al. 2011). 
 
1.2.1.3 Complications of Fasciotomy 
Surgical fasciotomy, although being the gold standard treatment of CS, it is not 
without its risks and complications. A high percentage of patients report postoperative 
neurologic symptoms and chronic pain associated with their surgical wounds (Fitzgerald, 
Gaston et al. 2000). Other complications include dry skin, pruritus, wound discolouration, 
swelling, tendon tethering, hypertrophic scarring, ulceration and muscle herniation 
(Johnson, Weaver et al. 1992, Heemskerk and Kitslaar 2003, Schmidt 2007). The risk of 
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infection is also not insignificant, and can create potentially devastating complications; 
this is directly related to the timing of the surgical intervention. 
Fasciotomies which are delayed for greater than 12 hours have a 28% rate of 
infection, while those performed early have an infection rate of 7.3% (Williams, Luchette 
et al. 1997). In a retrospective study looking at a trauma patient population, Dover et al 
(2011) found an early post-operative complication rate of 20%. Of these, 80% 
experienced clinical symptoms which they rated as severe. On long-term follow-up, 70% 
of patients experienced persistent symptoms, which severely limited them from either an 
occupational or social point of view (Dover, Marafi et al. 2011, Dover, Memon et al. 
2012). 
Fitzgerald et al (2000) retrospectively assessed complications of fasciotomy in 
both upper and lower extremities over an 8-year period (Fitzgerald, Gaston et al. 2000). 
They found that one in every ten patients had chronic pain associated with their 
fasciotomy wounds and more than 20% of patients covered their scars due to the aesthetic 
appearance of the wound. They also found complications to be detrimental both socially 
and occupationally, with 28% of patients changing their hobbies and 12% having to 
change their occupation, secondary to the complications of their fasciotomy (Fitzgerald, 
Gaston et al. 2000). Another post-operative complication of surgical fasciotomies is CS, 
which has been found to occur in 3 to 20% of cases (Barr 2008), and is believed to be 
caused by excessive post-operative scar tissue formation and/or inadequate release of 
compartmental fascia (Schmidt 2007). 
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1.2.2 Non-Surgical Interventions 
Currently, non-operative treatment modalities for CS are utilized in cases where 
surgical fasciotomy is contraindicated: when the affected limb is nonviable due to severe 
ischemia, or missed CS (Schmidt 2007). Before 1911, non-operative treatment options 
mainly consisted of limb mobilization and muscle stretching in order to prevent or treat 
ischemic contractures. Today, the most common non operative treatment is the removal 
of a cast or occlusive splints in a patient who presents with symptoms suggestive of CS. 
In these cases, if symptoms persist, fasciotomy is indicated. 
The consequences of a missed CS or of delaying fasciotomy are significant, as a 
result, non-operative treatments have been limited to an adjunctive role to fasciotomy. It 
would be beneficial to develop non-surgical modalities that could prolong the treatment 
window between the onset of CS and the time where irreversible neurological, vascular 
or muscular changes occur. Potential medical treatments have been described in both 
animal models and human case series. These include mannitol (Better, Zinman et al. 
1991), hyperbaric oxygen (Wattel, Mathieu et al. 1998), tissue ultrafiltration (Odland, 
Schmidt et al. 2005), anti-inflammatories (Manjoo, Sanders et al. 2010) and anti-oxidants 
(Kearns, Daly et al. 2004).  
 
1.2.2.1 Mannitol 
Mannitol is an osmotic diuretic, volume expander and free radical scavenger. It is 
commonly used to acutely reduce intracranial pressure, prevent or treat acute kidney 
failure secondary to crush injuries as well as treat raised intraorbital pressure. Crush 
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injuries associated with CS can lead to rhabdomyolysis, acidosis, acute renal failure 
(ARF) and even death (Bywaters, Delory et al. 1941, Better and Stein 1990).  
The severity of rhabdomyolysis can be confirmed and clinically followed by 
measuring serum creatine kinase (CK) levels. One of the most severe complications of 
rhabdomyolysis is ARF, which has a mortality rate of 3-50% (Slater and Mullins 1998, 
Malinoski, Slater et al. 2004). One of the tenets in the management of the crush syndrome 
and rhabdomyolysis is aggressive fluid resuscitation, in an attempt to prevent both 
systemic and renal complications (Odeh 1991, Malinoski, Slater et al. 2004).  
 Mannitol has been shown to decrease extracellular fluid volume by promoting 
water and sodium excretion. It has been shown to reduce ICP in a canine model of CS 
(Better, Zinman et al. 1991). Daniels et al. (1998) described the case of a healthy 19–
years old male presenting with heat stroke, who subsequently developed a lower leg CS, 
and who was treated only with mannitol. The patient was discharged 10 days after his 
admission to the hospital, with only “mild residual weakness” in the involved leg 
(Daniels, Reichman et al. 1998). 
 
1.2.2.2 Hyperbaric Oxygen Therapy 
Hyperbaric oxygen therapy involves the medical use of oxygen at levels higher 
than the atmospheric content of 21%. Hyperbaric oxygen therapy creates a 3-fold 
increase in the oxygen diffusion into the tissues (Wattel, Mathieu et al. 1998). This 
allows continued delivery of oxygen even in the presence of ischemia. Hyperbaric 
oxygen has been described as either the main treatment, or as an adjunct for various 
medical conditions, such as decompression sickness, arterial gas embolism, smoke 
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inhalation, severe carbon monoxide (CO) poisoning, osteoradionecrosis, skin flap 
healing, clostridial myonecrosis and CS (Leach, Rees et al. 1998). 
With respect to CS, hyperbaric oxygen treatment is believed to exert its beneficial 
effects on intracompartmental bleeding, swelling and edema by causing oxygen-induced 
vasoconstriction and allowing oxygen perfusion at lower perfusion pressures (as are seen 
in situations of CS) (Nylander, Nordstrom et al. 1987). As the interstitial edema is 
decreased, flow through the microcirculation is restored, or at least improved. The benefit 
of hyperbaric oxygen therapy has been reported in several ischemia-related clinical 
scenarios including traumatic ischemic lesions, ulcerations, infections and open fractures 
(Smith, Stevens et al. 1961, Hanson, Slack et al. 1966, Szekely, Szanto et al. 1973). 
Published case studies have reported success in averting fasciotomy in patients presenting 
with CS (Strauss, Hargens et al. 1983, Wattel, Mathieu et al. 1998, Gold, Barish et al. 
2003); a recent case report by Karam et al. (2010) described the case of an NCAA 
football player with acute paraspinal CS following weight-lifting: he was successfully 
treated with forced diuresis and hyperbaric oxygen chamber treatment (Karam, 
Amendola et al. 2010).  
However, due to the lack of definitive evidence and the need for costly and 
specialized equipment, hyperbaric oxygen is infrequently used and currently seen only as 
an adjunct to, and not a substitute for, surgical fasciotomy.  
 
1.2.2.3 Tissue Ultrafiltration 
Tissue ultrafiltration (TUF) was first described as a method of analyzing the 
contents of the interstitial space (Linhares and Kissinger 1992). TUF involves the 
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insertion of small-diameter semi-permeable hollow fibers into the tissue compartment of 
interest. The catheter is connected to suction, in order to filter interstitial fluid. This 
enables researchers to not only decompress the tissues, but also analyze the extracted 
fluid for biomarkers (Odland, Schmidt et al. 2005).  The use of ultrafiltration in CS has 
been shown to lower the intramuscular pressure while maintaining perfusion pressure 
(Odland, Schmidt et al. 2005). In their porcine model of CS, using bovine serum 
albumin-enriched saline infusion into the anterior compartment of the hind limb, Odland 
et al. (2005) measured serum and filtrate creatinine kinase (CK) and lactate 
dehydrogenase (LDH) levels over a 10 hour period. They found that the biomarker levels 
were 80 times higher in the ultrafiltrate compared to the serum (Odland, Schmidt et al. 
2005). Significantly lower pressures were recorded in experimental limbs connected to 
negative pressure, coupled with a markedly lessened cellular injury. The authors 
undertook a small human clinical trial, to test the safety and efficacy of ultrafiltration. 
They examined ten patients with tibial fractures treated with intramedullary nailing with 
and without tissue ultrafiltration, and found no difference in ICP between the two groups; 
however, 2 patients in the control group developed CS, while none in the ultrafiltration 
treatment group (Odland and Schmidt 2011). 
 
1.2.2.4 Anti-Inflammatories 
There is a significant body of evidence describing an increase in ICP as the 
underlying cause of microcirculatory dysfunction. However, the significant impact of 
inflammation and leukocyte activation in the pathophysiology of CS is increasingly being 
recognized (Lawendy, Sanders et al. 2011, Lawendy, Bihari et al. 2015). Activated 
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leukocytes directly impair perfusion, increase intravascular protein leakage, thus 
contributing to tissue edema, as well as causing direct parenchymal injury (Kurose, 
Anderson et al. 1994, Forbes, Carson et al. 1995, Forbes, Harris et al. 1996, Harris and 
Skalak 1996). 
Non-steroidal anti-inflammatory drugs (NSAIDs) are a class of medication that 
interfere with arachidonic acid metabolism, via inhibition of the cyclooxygenase (COX) 
enzyme. Two isoforms have been identified: the constitutively expressed COX-1, and 
inducible COX-2. COX-2 expression can be upregulated in response to inflammatory 
stimuli and pro-inflammatory cytokines (Jan and Lowry 2009). Manjoo (2010), looked at 
the effects of indomethacin, a selective COX-2 inhibitor, on capillary perfusion, cell 
damage and inflammatory activation in a rat model of CS. They found that indomethacin 
improved tissue perfusion and viability, decreased the number of non-perfused capillaries 
and significantly lowered tissue injury, lending support to the suggestion that anti-
inflammatory treatments have the potential to reduce the damage in the presence of 
elevated ICP (Manjoo, Sanders et al. 2010). 
 
1.2.2.5 Anti-Oxidants 
Ischemia-reperfusion is known to lead to a significant release of reactive oxygen 
species (ROS) – extremely damaging free radicals, both locally within the tissue, as well 
as from the release of activated neutrophils. Thus, the resulting tissue injury is not only 
seen at the local level in skeletal muscle, but also in distant organ systems, such as the 
lungs and kidneys (Xiao, Eppihimer et al. 1997, Kearns, Kelly et al. 1999). In a study by 
Perler et al. (1990), the authors concluded that the most important component of CS 
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appeared to be the free radical-mediated reperfusion injury: an increase in free radicals 
(such as H2O2) causes direct injury to the endothelium. Furthermore, by interacting with 
lymphocytes, ROS further stimulate a pro-inflammatory state by increasing cytokines 
levels (e.g. TNF-ɑ and IL-8) (Perler, Tohmeh et al. 1990). These, in turn, lead to the 
activation of neutrophils and these activated neutrophils then release ROS, which further 
contributes to the endothelial injury.   
Due to expanding knowledge regarding the contribution of oxidative damage in 
CS and ischemia-reperfusion injury, various anti-oxidant therapies have been attempted, 
to prevent both the local and systemic injuries. These include N-acetylcysteine (NAC), 
taurine and vitamin C. NAC is a free radical scavenger that also restores the host cellular 
anti-oxidant defenses by upregulating glutathione levels in the cell (Sjodin, Nilsson et al. 
1989). The primary clinical use of NAC is in acetaminophen overdose, to reduce injury to 
hepatocytes (Flanagan and Meredith 1991). It is also used for its nephroprotective effects 
in patients with kidney failure prior to administering IV contrast (Tepel, van der Giet et 
al. 2000), as well as to protect against oxidative injury in lung parenchyma (Bernard 
1991). A study by Kearns et al. (1999) examining the effects of NAC in a rat model of 
CS found that CS led to decreased muscle contractility and increased tissue 
myeloperoxidase activity and treatment with NAC attenuated neutrophil activation and 
preserved muscle contractility (Kearns, Kelly et al. 1999).  
Taurine (2-aminoethane sulfonic acid) is a sulphur-containing amino acid, derived 
from the metabolism of methionine. The major source of taurine is from a person’s diet. 
Taurine has been implicated in the inhibition of lipid peroxidation, cell membrane 
stabilization, osmoregulation, as well as modulation of calcium levels (Kingston, Kelly et 
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al. 2004). Studies have found that exogenous administration of taurine can have 
protective effects against ischemia-reperfusion tissue injury in the kidney, heart, liver and 
skeletal muscle (Oz, Erbas et al. 1999, Wettstein and Haussinger 2000, Michalk, 
Hoffmann et al. 2003, Wang, Li et al. 2005). Wang et al. (2005) found that the 
administration of taurine reduced anterior compartment pressure, muscle edema, lactate 
dehydrogenase and lipid peroxidation products in a rabbit model of CS (Wang, Li et al. 
2005).  
Vitamin C (ascorbate) is an antioxidant that has been shown to decrease or 
prevent reperfusion injury in the lung and skeletal muscle, as well as to reduce oxidant 
production in neutrophils (Herbaczynska-Cedro, Wartanowicz et al. 1994, Lehr, Frei et 
al. 1995, Kearns, Kelly et al. 1999, Armour, Tyml et al. 2001, Kearns, Moneley et al. 
2001). It has scavenging effects on hydrogen peroxide, which is an important component 
for neutrophils recruitment and adhesion (Armour, Tyml et al. 2001). Vitamin C also 
targets circulating neutrophils and lymphocytes (Levine, Daruwala et al. 1998). It is 
believed to exert its beneficial effects by reducing neutrophil recruitment and activation, 
as well as their extravasation into the tissues by altering the expression of adhesion 
molecules (e.g. ICAM-1). Vitamin C has also shown promising results in 
prophylactically treating complex regional pain syndrome (CRPS) or reflex sympathetic 
dystrophy (Zollinger, Tuinebreijer et al. 1999). While CRPS and CS are distinct 
pathological entities, they do share certain underlying physiological processes such as an 
exaggerated inflammatory response, peripheral nervous system dysfunction and an 
increase in circulating free radicals causing lipid membrane oxidation (Van der Laan 
1997). A study by Kearns et al., 2004 using a rat cremasteric muscle model of CS, found 
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that pre-treatment with Vitamin C reduced intercellular adhesion molecule-1 (ICAM-1) 
expression and myeloperoxidase (MPO) activity as well as muscle swelling, while 
preserving muscle contractile function (Kearns, Daly et al. 2004). Although there is a 
concern that vitamin C may have pro-oxidant properties when administered at high doses 
for a prolonged period of time (Podmore, Griffiths et al. 1998), it has been shown to have 
a potent antioxidant effect without associated toxicity at doses less than 500mg per day 
(Bendich and Langseth 1995). 
 
 
1. 3 PATHOPHYSIOLOGY OF CS 
The pathophysiology underlying the onset, progression and muscle necrosis 
associated with CS is only partially understood. A bony or soft tissue insult, combined 
with an inherently rigid and unyielding fascia which prevents volume expansion leads to 
increased ICP, which, in turn, leads to microcirculatory dysfunction. This is followed by 
the activation of an inflammatory cascade and tissue edema, eventually leading to 
impaired gas exchange, restricted oxygen and nutrient delivery. The final common 
pathway is cellular anoxia, cell death and myonecrosis.   
In 1881, Volkmann was the first to suggest that limb paralysis secondary to CS 
was due to the interruption in arterial blood supply, causing ischemia (von Volkmann 
1881). He described the devastating hand deformity seen in the paediatric population 
following a supracondylar fracture, complicated by CS. The deformity still bears his 
name today. However, Volkmann was unable to describe the cause of the ischemia. Leser 
in 1884 expanded on this principle and confirmed, through well-designed animal 
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experiments, that muscle necrosis was a crucial part of the condition (Leser 1884). 
Hildebrand in 1906 demonstrated that nerve involvement also occurred, in addition to 
muscle necrosis (Hildebrand 1906).  Over the last century, various theories have been 
offered and expanded upon to explain the pathophysiological basis of CS. These have 
included neurological injury (Thomas 1909), arterial injury and spasm (Griffiths 1940), 
venous obstruction (Murphy 1914, Brooks 1922), increased ICP and pressure-induced 
ischemia (Jepson 1926). 
In 1940, while trying to expand on Volkmann’s findings, Griffiths suggested that 
the paralysis and contractures seen were due to an underlying arterial injury with 
reflexive spasms (Griffiths 1940). The idea of arterial injury and spasm as a cause of 
ischemia and contractures was further supported by Watson-Jones in 1952 (Watson-Jones 
1952). Foisie in 1942 believed that autonomic dysfunction mediated the arterial spasm. 
As a result, he suggested that autonomic sympathetic blockade could treat CS and prevent 
the complications (Foisie 1942). We now know that this was incorrect, on both a 
pathophysiological and clinical basis.  
The connection between ICP and subsequent ischemia was first made by Hughes 
in 1948 (Hughes 1948) and in 1975, while considering the link between pressure, 
ischemia, muscle injury and the importance of compartmental decompression through 
fasciotomy, Matsen combined these relevant concepts into one unified theory of CS 
(Matsen 1975). Through his description, Matsen confirmed that CS could occur in any 
anatomical location, and was not a condition exclusive to the upper extremity. In 
addition, he suggested that the increase in tissue intracompartmental pressure was a 
critical underlying feature in the development of CS and furthermore, that surgical 
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fasciotomy was the only effective treatment (Matsen 1975). Whitesides (1975) then 
helped to define a methodology for directly measuring ICP (Whitesides, Haney et al. 
1975). Initially, a threshold ICP was believed to exist above which irreversible changes 
and injury would occur (Heckman, Whitesides et al. 1993). Subsequently, rather than an 
absolute pressure threshold, others suggested that it is the difference between ICP and 
diastolic blood pressure that was relevant, and should be considered in the assessment of 
patients (Har-Shai, Silbermann et al. 1992, Heckman, Whitesides et al. 1994, Bernot, 
Gupta et al. 1996).  
 
1.3.1 Ischemia 
1.3.1.1 Microvascular Dysfunction 
Three theories have attempted to describe the microcirculatory dysfunction and 
ischemia associated with increased tissue pressure seen in CS: microvascular occlusion 
theory, critical closing pressure theory and arterio-venous gradient theory.  
The microvascular occlusion theory states that CS results from capillary occlusion 
caused by increased ICP. The theory postulates that increased ICP above capillary 
pressure leads to a reduction in the patency of capillaries and thus subsequent blood flow. 
This then creates an ischemic state, impairing gas exchange and nutrient delivery, leading 
to cellular anoxia and cell death. However, a study by Hartsock et al (1998) found that 
while compartment pressures could be experimentally raised well beyond the level to 
cause complete cessation of capillary blood flow, collapse of capillary vessels was not 
seen, essentially discrediting the microvascular occlusion theory (Hartsock, O'Farrell et 
al. 1998).  
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The critical closing pressure theory describes an absolute ICP above which 
arteriole closure occurs, caused by an elevated differential between tissue pressure and 
intravascular pressure (Burton and Yamada 1951). This would then lead to arteriolar 
collapse and tissue ischemia. The validity of this theory however was put into question by 
an experiment by Vollmar et al (1999) who assessed the response of arterioles, capillaries 
and venules to pressure elevation and found no signs of arteriolar spasm or collapse 
(Vollmar, Westermann et al. 1999).  
Finally, the arterio-venous gradient theory states that CS is caused by increased 
tissue pressure, which reduces the pressure gradient from the high pressure seen in the 
arterial system to the low pressure on the venous side. As ICP rises, the gradient is 
reduced and blood flow decreases, causing cellular anoxia and tissue injury (Matsen, 
Winquist et al. 1980). This phenomenon also leads to pooling of venous blood, fluid 
extravasation, interstitial edema and swelling and causes a further rise in ICP (Matsen 
and Krugmire 1978). Although all three theories attempt to explain the link between 
raised ICP and microcirculatory dysfunction, the AV gradient theory provides the closest 
link, and is most easily reconciled with our current understanding of CS and 
microcirculatory dysfunction vis-à-vis pressure gradient changes. 
 
1.3.1.2 Low Flow Ischemia 
We now know that, rather than being due to a state of complete occlusive vascular 
ischemia and spasm, CS creates a microcirculatory “low flow” environment, occurring in 
the presence of patent arterial vessels. Under normal conditions, microvascular perfusion 
consists of predominantly continuously perfused capillaries (CPC). As the ICP rises, 
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there occurs a shift in perfusion toward intermittently perfused capillaries (IPC), and 
nonperfused capillaries (NPC) (Lawendy, Sanders et al. 2011, Lawendy, Bihari et al. 
2015). Lawendy (2011) used intravital video microscopy (IVVM) to directly observe the 
microvascular perfusion changes seen in early CS. After artificially raising ICP in a rat 
model of CS, a decrease in the number of CPC (representing healthy perfusion) and an 
increase in intermittent and non-perfused capillaries was found. These changes in 
microvascular perfusion were accompanied by significant leukocyte activation, as well as 
parenchymal injury (Lawendy, Sanders et al. 2011).  
Despite the presence of microvascular dysfunction, some degree of perfusion 
remains during CS, creating a “low flow” ischemic state, where CPCs are present in the 
same capillary bed as IPC and NPC. NPCs have no ability for nutrient or gas exchange, 
and represent a state of ischemia, unable to meet the metabolic demands of the tissue 
(Lawendy, Sanders et al. 2011). This creates a partial ischemic state, which triggers an 
early and significant inflammatory response (Gute, Ishida et al. 1998, Lum and Roebuck 
2001, Schlag, Harris et al. 2001). 
 Heppenstall (1986) considered the ischemic process in CS in a canine model. 
They found that the low flow ischemic state (specifically associated with CS) caused 
tissue injury that was significantly greater than what was seen in a state of complete 
ischemia. This finding was believed to be due to the intense inflammatory reaction 
(Heppenstall, Scott et al. 1986). The association between partial ischemia and intense 
inflammatory response has been substantiated by Conrad (2005), who compared partial 
and complete ischemia in a murine model. Conrad’s results indicated that a partial 
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ischemic state caused a significant early increase in pro-inflammatory mediators when 
compared to complete ischemia (Conrad, Stone et al. 2005).  
There are important distinctions which must be drawn between CS and complete 
ischemia-reperfusion (I/R) injury: CS causes tissue injury and necrosis despite a patent 
macrocirculatory system in the face of a palpable distal pulse (Seddon 1966). In addition, 
the injury occurring as a result of CS is of greater magnitude compared to a complete 
ischemic insult of the same duration (Heppenstall, Scott et al. 1986). While our 
understanding of the pathophysiological basis underlying CS is not complete, 
microcirculatory dysfunction caused by an ongoing ischemia-reperfusion type injury, 
early leukocyte activation and a pro-inflammatory state appear to be the driving forces 
behind the generation of CS, and its potentially devastating sequelae. 
 
1.3.2 Reperfusion and Inflammation 
The greatest paradigm shift with respect to our understanding of the 
pathophysiology underlying CS came in 1941 during World War II. Researchers noted 
the systemic clinical collapse which occurred in otherwise stable patients following the 
revascularization of injured limbs. They noted a decrease in urine output, clinical 
deterioration and multi-organ failure, followed by death in certain cases. Interestingly, 
this occurred even when the injured limbs had been amputated (Bywaters and Beall 1941, 
Bywaters, Delory et al. 1941). This led to the concept of ‘crush syndrome’, defining the 
clinical entity associated with what we know today as ‘reperfusion injury’.  
Reperfusion injury occurs when tissues are perfused after a period of ischemia. 
This is accompanied by an intense inflammatory response, with both local and systemic 
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effects. The return of oxygen during reperfusion causes the formation of reactive oxygen 
species (ROS), which, along with activated neutrophils, cause the local and systemic 
injury seen following reperfusion.  
It has been well documented, in complete ischemia-reperfusion (I/R), that 
increasing ischemia time leads to an increasing accumulation of activated leukocytes 
(particularly neutrophils) in the post-capillary venules.  Neutrophils contain intracellular 
granules made up of various proteases and myeloperoxidase, which are very damaging to 
cellular and extracellular targets. Upon activation, these granules are released into the 
affected tissues. Thus, leukocyte activation leads to increased vascular permeability to 
plasma protein leakage, tissue edema, and increased interstitial pressure. An increase in 
interstitial pressure is believed to physically compress capillaries altering the arterial 
venous gradient, leading to further failure of capillaries to reperfuse upon restoration of 
blood flow. Correlation has been noted between the number of leukocytes in the 
capillaries of post-ischemic tissue and the percentage of capillaries exhibiting no-reflow 
(Engler, Dahlgren et al. 1986, Barroso-Aranda, Schmid-Schonbein et al. 1988, Gute, 
Ishida et al. 1998). 
The I/R process also leads to the expression of cell surface ischemic antigens; this 
leads to complement activation cascade, which eventually results in the formation of the 
membrane attack complex (MAC). In addition, cytokines are also released, providing 
signals between the responding immunological cells, leading to adhesion, migration and 
extravasation (Ley 2008).  
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1.3.2.1 Reactive Oxygen Species (ROS) 
ROS are small chemically reactive substances containing oxygen. These include 
peroxides, superoxide and hydroxyl radical. ROS are formed as a normal byproduct of 
the mitochondrial electron transport chain, peroxisomal fatty acid metabolism and 
oxygen metabolism, and play an important role in cellular signalling as well as 
maintenance of homeostasis (Toyokuni 1999).  
During periods of ischemia, xanthine oxidase (XO) (an enzyme located in 
microvascular endothelial cells of skeletal muscle) is converted from its oxidized 
nicotinamide-adenone dinucleotide (NAD+)-dependent dehydrogenase (XDH) state into 
XO (Korthuis, Granger et al. 1985, Korthuis, Grisham et al. 1988, Carden, Smith et al. 
1990, Carden, Smith et al. 1991). Upon reperfusion (ie: the re-introduction of oxygen), 
molecular oxygen now acts as the substrate which XO converts to ROS, such as 
superoxide and hydroxyl radicals. The newly formed ROS will cause further tissue 
damage by attacking cell membrane lipids, proteins and glycosaminoglycans. 
Furthermore, the process will further stimulate the pro-inflammatory state, bringing 
leukocytes to the affected tissues. 
Under normal conditions, host cells are protected from the damaging effects of 
ROS by endogenous anti-oxidants, such as superoxide dismutase, catalase and 
glutathione peroxidase. During oxidative stress, when ROS overwhelm the anti-oxidant 
defense of the host, ROS will damage cellular membranes, and as a result, severe 
cellular/tissue damage ensues. 
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1.3.2.2 Endothelial Activation 
Under normal circumstances, resting endothelial cells do not interact with 
leukocytes; on the contrary, they actually play a role in maintaining leukocyte quiescence 
(Ley, Laudanna et al. 2007). Leukocyte quiescence is due, in part, to adhesion molecules 
not being expressed (like E-selectin or VCAM-1), expressed at very low levels (like 
ICAM-1), or sequestered internally (like P-selectin). In response to reperfusion injuries, 
the activation of endothelial cells consists of three time-dependent stages: immediate 
(within minutes), acute (within hours) and chronic (within days) (Ley and Reutershan 
2006). The immediate activation of endothelial cells is triggered by inflammatory 
chemokines, which leads to endothelial degranulation and contraction (Maier and Bulger 
1996). P-selectin, which is normally stored within the cytoplasmic Weibel-Palade bodies, 
is delivered to the cell surface and functions to facilitate leukocyte recruitment (Weibel 
and Palade 1964), by interacting with the P-selectin glycoprotein ligand-1 (PSGL-1) 
found on leukocytes. 
The acute endothelial activation is triggered by the release of pro-inflammatory 
cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β); 
this leads to an upregulation of gene transcription and production of E-selectin, as well as 
ICAM-1 (Kurose, Anderson et al. 1994, Gute, Ishida et al. 1998, Ley, Laudanna et al. 
2007). The process appears to be reversible once the source of inflammation is resolved 
(Ley, Laudanna et al. 2007).  
 
	 32 
1.3.2.3 Cytokines/Chemokines 
Cytokines and chemokines are a family of cell-derived secreted polypeptides that 
act as communication messengers between cells (Feghali and Wright 1997). They can 
communicate through autocrine, paracrine and/or endocrine mechanisms. Chemokines 
are a subset of cytokines possessing chemotactic properties. These messengers are 
responsible for cellular activation, communication, feedback loops and the initiation of 
the systemic response to inflammation. The majority of cytokines are multifunctional 
and, through their binding to cell surface receptors, can initiate a series of intracellular 
signal transduction pathways (Feghali and Wright 1997). 
Cytokines can alter the expression of various transcription factors and, therefore, 
regulate gene transcription, further altering and modifying the production of cytokines 
and cell surface receptors. Their effects are varied, and include synergistic and 
antagonistic action, as well as exerting both negative and positive feedback regulatory 
loops. They provide signals between leukocytes and endothelial cells eventually leading 
to adhesion and transmigration of leukocytes (Gillani, Cao et al. 2012). 
Acute inflammatory reactions, such as those seen in I/R injury and CS, are 
mediated by a number of pro-inflammatory cytokines, most notably IL-1β, TNF-ɑ, IL-6, 
IL-8, thromboxane A2; these are produced in the acute phase of inflammatory response. 
Their upregulation stimulates downstream leukocyte activation and recruitment to the 
involved tissues. The end result is the effects on leukocyte activation, increased reactive 
oxygen species, the production and upregulation of adhesion molecules, phagocytosis and 
apoptosis.  
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1.3.2.3.1 TNF-a 
TNA-a is a pro-inflammatory cytokine produced by macrophages following an 
appropriate stimulus such as trauma, inflammation or infection (Stein and Gordon 1991). 
It is one of the first cytokines released as the inflammatory process is initiated. It has 
multiple functions, including being a chemoattractant for surrounding neutrophils, and is 
involved in the upregulation of downstream cytokine production (Ascer, Gennaro et al. 
1992). It binds to and exerts its effects through two transmembrane receptors, TNFR1 
and TNFR2 (Banner, D'Arcy et al. 1993). Binding and subsequent activation leads to 
altered gene transcription and protein coupling, which has been shown to initiate 
programmed cell death pathways (Wallach 1997, Jiang, Wang et al. 2009). In a study by 
Jiang et al. looking at hind limb ischemia in TNFR1 knockout mice, by blocking the 
TNF-a/TNFR1 pathway, it was found that they could prevent the downstream actions of 
TNF-a and decrease programmed cell death (Jiang, Wang et al. 2009). In a rat model of 
CS, systemic levels of TNF-ɑ, along with other cytokines such as Il-1β, GRO/KC, MCP-
1, MIP-1a and IL-10 were found to increase in response to elevation of ICP (Donohoe 
2015); however, unlike in complete I/R (characterized by TNF-ɑ spike), TNF-ɑ levels 
continued to increase following fascial decompression (Lawendy, Bihari et al. 2014, 
Lawendy, Bihari et al. 2016). This second rise in TNF-a levels is described by the 
authors as a second hit (Lawendy, Bihari et al. 2016) and likely due to the liberation of 
cellular debris, pro-inflammatory mediators and cytokines into the systemic circulation 
(Lawendy, Bihari et al. 2016). The second hit and washout of debris is also significant in 
that it suggests that CS, rather than being purely an I/R phenomenon is more consistent 
with a pro-inflammatory state. Their research, along with previous work on the systemic 
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effects of I/R, has shown that the release of TNF-a and other inflammatory cytokines in 
response to a local ischemic event can cause significant systemic injury (Brock, Lawlor et 
al. 1999, Lawlor, Brock et al. 1999, Lawendy, Bihari et al. 2016). 
 
1.3.2.3.2 IL-1 β 
IL-1β, like TNF-a, is a pro-inflammatory cytokine produced by activated 
macrophages, and is involved in cell proliferation, differentiation and programmed cell 
death (Gao, Madi et al. 2014). IL-1β has been shown to play a significant role in the I/R 
literature and multiple studies have shown significant increases in IL-1β levels associated 
with I/R events (Rothwell, Allan et al. 1997, Touzani, Boutin et al. 1999, Pomerantz, 
Reznikov et al. 2001, Furuichi, Wada et al. 2006, Simi, Lerouet et al. 2007). Studies 
utilizing IL-1β knockout mice have shown significant reduction in ischemia-induced 
inflammatory responses (Furuichi, Wada et al. 2006). The same authors have further lent 
credence to the idea that IL-1β mediates the injury seen in I/R injury from improvements 
seen with IL-1-targeted therapy in these experimental models (Touzani, Boutin et al. 
1999, Pomerantz, Reznikov et al. 2001, Furuichi, Wada et al. 2006). A study by Kalns et 
al., looking at extremity CS in a pig model, in order to assess the impact of normobaric 
vs. hypobaric situations in relation to CS, found that levels of IL-1β, along with TNF-a, 
IL-6, FGF, IGF-1, IGF-BP4/BP5 and others were elevated in experimentally-induced CS 
(Kalns, Cox et al. 2011, Kalns, Cox et al. 2011). A study by de Franciscis (2016) assessed 
biomarker changes in patients with arterial occlusion and CS. All ischemic patients 
experienced a significant rise in levels of IL-1, IL-6, IL-8 and TNF-a, and patients 
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requiring a fasciotomy had higher levels of these pro-inflammatory mediators compared 
to the patients that did not require a fasciotomy (de Franciscis, De Caridi et al. 2016).  
 
1.3.2.4 Leukocyte Activation 
The increased ICP leads to a low flow ischemic state, which is associated with 
significant leukocyte activation that contributes to microcirculatory dysfunction and 
leukocyte accumulation in post-capillary venules (Lawendy, Bihari et al. 2015). The 
complex and regulated leukocyte activation cascade was first described in 1839 by 
Rudolph Wagner (Wagner 1839). The cascade is initialized by the release of 
inflammatory cytokines and chemokines, which then trigger the upregulation and 
differential expression of various classes of adhesion molecules such as selectins, 
integrins and Ig superfamily, on both the endothelium and leukocytes (Ley 2008).  
The activation cascade is comprised of several highly regulated stages (Figure 
1.2). The first step is the capture of the leukocyte by the activated endothelium. This 
process is mediated by selectins, such as L-selectin on leukocytes and P-selectin and E-
selectin expressed on endothelial cells. The next step is leukocyte “rolling”, whereby the 
leukocyte attaches itself to the surface of the endothelium. The process then progresses to 
the slow rolling stage, mediated by integrins. This is then followed by the firm adhesion 
of leukocytes to the endothelium. This adhesion is further strengthened and then followed 
by the clustering of integrins, which, under the appropriate stimuli, leads to leukocyte 
transmigration and extravasation into the interstitium  (Ley, Laudanna et al. 2007).  
The process of adhesion and extravasation is mediated by members of the Ig 
superfamily such as ICAM-1 and VCAM-1 on the endothelial surface, and PECAM-1 on 
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neutrophils (Albelda, Muller et al. 1991, Barreiro, Yanez-Mo et al. 2002, Yang, Froio et 
al. 2005). Following leukocyte extravasation into the sub-endothelial matrix and 
migration towards the site of injury, a positive feedback loop is created, increasing the 
permeability of the endothelium, leading to further intravascular protein extravasation. 
This manifests clinically as significant interstitial edema and swelling, which in itself will 
amplify the increase in ICP (Gute, Ishida et al. 1998).  
Several studies have examined CS using intravital video microscopy (IVVM), a 
modern technique which allows for the direct visualization of microvascular perfusion 
(Manjoo, Sanders et al. 2010, Lawendy, Sanders et al. 2011, Lawendy, Bihari et al. 
2014). They have demonstrated a significant increase in activated leukocytes in the post-
capillary venules of skeletal muscle. Furthermore, activated leukocytes also appear to 
contribute to the parenchymal injury directly, as demonstrated in neutropenic rats 
(Lawendy, Bihari et al. 2015). 
 
1.3.2.5 Complement 
The complement system forms part of the innate immunity which acts as a 
mediator between the innate and acquired immunity response pathways. The function of 
the complement system is to clear pathogens from the host organism (Ricklin, 
Hajishengallis et al. 2010). The complement cascade is made up of a series of proteins on 
cell surfaces and in plasma, many of which exist as precursors, and are activated at the 
site of inflammation. The complement system mediates a sequence of events that begins 
with inflammatory activation and ends with pathogen opsonisation and lysis.   
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Figure 1.2. Leukocyte activation cascade. Leukocyte activation is an orderly process 
comprised of leukocyte capture, rolling, adhesion and extravasation. The 
individual steps are mediated by differential expression of various 
adhesion molecules on both the leukocyte and the endothelium. 
 Adapted from Ley, Laudanna et al. 2007. 
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The complement cascade is activated by IgG and IgM antibodies. There are three 
known biochemical pathways that activate the complement system: the classical pathway, 
the alternative pathway and the lectin pathway (Zipfel and Skerka 2009). During I/R, the 
presence of ischemia antigens on cell surfaces triggers binding of circulating IgM which 
subsequently leads to complement activation and formation of C3a/C3b. This is then 
followed by the formation of the membrane attack complex (MAC), mediating the local 
cellular injury response (Gillani, Cao et al. 2012). MAC is also involved in the 
inflammatory amplification through stimulation of arachidonic acid metabolism, release 
of prostaglandin E2, leukotriene B4, thromboxane B2, prostanoids, IL-1 and ROS 
(Hansch, Seitz et al. 1984, Hansch, Seitz et al. 1987, Gillani, Cao et al. 2012). 
 
Inflammatory processes such as leukocyte activation, cytokine release and the 
complement cascade as well as ROS production serve a useful and protective function 
including cleanup of diseased/dead cells and initiate tissue repair mechanisms. 
Unfortunately, in overwhelming inflammation, as is seen in various states such as 
ischemia-reperfusion injury and CS, these pathways contribute to the extensive tissue and 
organ damage. 
 
 
1.4 HEME METABOLISM AND OXIDATIVE STRESS 
Oxygen is inherently toxic but living organisms have evolved the ability to utilize 
this gas, as well as coping mechanisms to deal with oxidative stress. Most notable of 
these strategies, is the presence of the heme oxygenase (HO) enzyme.  
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HO degrades heme, forming equimolar amounts of biliverdin, free iron and 
carbon monoxide (CO) (Ryter, Alam et al. 2006) (Figure 1.3). There are three separate 
HO isoforms: the constitutively expressed HO-2 and HO-3, and the inducible HO-1 
(Maines, Trakshel et al. 1986, McCoubrey, Huang et al. 1997).  
The importance of CO and the HO enzyme has been shown in case reports which 
detailed the death of individuals who lacked the enzyme (Yachie, Niida et al. 1999). 
Several studies have demonstrated that the inhibition of HO (by pharmacological or gene 
knockout means) was found to be a lethal mutation and detrimental to the host due to 
heightened sensitivity to cellular stress (Poss and Tonegawa 1997, Dungey, Badhwar et 
al. 2006). Conversely, the upregulation of HO (pharmacologically or through transfection 
with adenovirus containing HO gene construct) has been found to be protective against 
ischemia-reperfusion injury (Otterbein, Kolls et al. 1999, Otterbein, Lee et al. 1999, 
McCarter, Akyea et al. 2004, McCarter, Badhwar et al. 2004) Badhwar et al. 2004). 
There are case reports which have suggested that individuals with higher 
expression of HO enzyme are less likely to develop diabetes, atherosclerosis, chronic 
obstructive pulmonary disease and arthritis (Yamada, Yamaya et al. 2000, Brydun, 
Watari et al. 2007, Wagener, Toonen et al. 2008, Song, Bergstrasser et al. 2009, 
Motterlini and Otterbein 2010). As upregulation of HO is not clinically feasible, further 
research has looked at the downstream byproducts of the heme degradation pathway, 
particularly CO, to examine its contribution to the observed protective effects.  
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Figure 1.3. Heme degradation pathway. Heme, derived from hemoglobin, is broken 
down into biliverdin by heme oxygenase (HO). Biliverdin is then 
converted into bilirubin by biliverdin reductase (BVR). In this process, 
carbon monoxide (CO) and free iron (Fe2+) are generated. 
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1.4.1 Carbon Monoxide 
Carbon monoxide (CO) is a freely diffusible gas that traverses all cell membranes. 
Although considered a ubiquitous pollutant and a dangerous inhalation hazard, it is 
present in every mammalian cell (Coburn 1967).  Small and regulated amounts of 
intracellular CO are continuously produced: the rate of endogenous CO production is 
approximately 0.42ml/hr (Coburn, Williams et al. 1967); approximately 86% of 
endogenous CO production comes from the metabolism of heme, while the remaining 
14% is derived from lipid oxidation, xenobiotic metabolism and other metabolic 
processes (Vreman, Wong et al. 2000, Archakov, Karuzina et al. 2002). The endogenous 
production of CO has been found to increase under cellular stress arising from certain 
toxicological and pathological conditions (Zayasu, Sekizawa et al. 1997).  
Claude Bernard, in 1857, was the first to describe the binding of CO to heme 
within the hemoglobin molecule, leading to the formation of carboxyhemoglobin (COHb) 
(Bernard 1857). This was then followed in 1912 by Douglas, demonstrating that the 
binding of CO to heme was reversible (Douglas, Haldane et al. 1912). Importantly, the 
affinity of CO for heme is approximately 240 times that of oxygen (Weaver 1999). One 
molecule of hemoglobin has four oxygen binding sites. When two of the binding sites are 
occupied by CO molecules (i.e. half saturation), the release of oxygen from the remaining 
binding sites is inhibited, leading to a reduction in the oxygen-carrying capacity of 
hemoglobin and subsequent hypoxia (Weaver 1999). By exposing the body to supra-
physiologic oxygen levels, such as is seen with hyperbaric oxygen therapy, oxygen can 
outcompete CO for the hemoglobin binding sites, and thus reverse the hypoxia seen with 
CO poisoning (Weaver 1999, Gorman, Drewry et al. 2003).  
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Under normal conditions, the majority of blood COHb comes from endogenous 
production, and corresponds to blood CO levels of 0.4-1% (Vreman, Wong et al. 2000).  
Symptoms of CO poisoning begin to manifest at around 20% COHb levels and include 
dizziness, drowsiness, headache, vomiting and loss of motor coordination. Prolonged 
exposure, and COHb levels of 50-80% will lead to respiratory difficulty, disorientation, 
chest pain, loss of consciousness, coma and even death (Weaver 1999). 
 
1.4.2 Biological Effects of Carbon Monoxide 
While history has focused mostly on the negative impact of CO, namely CO 
poisoning, CO plays an important and positive role in cellular communication. CO is an 
important mediator of cell signalling, and appears to possess anti-ischemic, anti-oxidant, 
anti-inflammatory, anti-apoptotic and vasodilatory properties (Kim, Ryter et al. 2006). 
 
1.4.2.1 Cellular Signalling 
There are currently a few known cellular mechanisms over which CO has 
particular influence. The modulation of soluble guanylate cyclase (sGC) by CO and the 
subsequent production of cGMP is currently the most commonly described mode of 
action (Ryter and Otterbein 2004). The binding of CO to the heme domain within sGC 
stimulates its activity and this leads to a significant increase in cGMP. Studies have 
shown that directly subjecting vascular smooth muscle cells to CO or hypoxia (via an 
increase in HO-1 and subsequently increased CO) leads to an increase in cGMP levels 
(Morita, Perrella et al. 1995). 
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In addition to the direct CO binding sGC signaling pathway, other indirect 
pathways have been identified such as modulation of mitogen-activated protein kinases 
(MAPK) and upregulation of calcium-dependent potassium channel activity (Ryter, 
Otterbein et al. 2002). We do know that there is a significant interaction and cross talk 
between CO and other endogenously produced gases (e.g. nitric oxide, hydrogen sulfide) 
in the biologic systems (Kajimura, Fukuda et al. 2010), although the intricacies of the 
underlying mechanism and signalling pathways have yet to be elucidated. 
 
 
1.4.2.2 Vasodilation 
Several cellular mechanisms are believed to be involved in the vasodilatory effect 
of CO. CO has both “direct” (i.e. endothelial independent) effects on vascular smooth 
muscles cells, as seen with the modulation of sGC and subsequent increase in cGMP, as 
well as endothelial-dependent changes in the expression of vasoconstrictor factors 
(Motterlini and Otterbein 2010). CO has been shown to target vascular smooth muscle 
cells and is, therefore, able to have a significant vasodilatory impact, which has been 
reported in the cardiac, renal, pulmonic and cerebral vasculature (Sylvester and 
McGowan 1978, McFaul and McGrath 1987, Abraham and Kappas 2008). In addition to 
the role played by sGC and the subsequent increase in cGMP in vasodilatory role of CO, 
CO has also been shown to directly activate calcium-dependent potassium channels in the 
peripheral vasculature, causing vasodilatation (Wang, Wang et al. 1997). Studies which 
attempted to block the pathway using ryanodine, a known calcium channel blocker, were 
able to inhibit CO-induced vasodilatation (Jaggar, Leffler et al. 2002). In addition to the 
direct peripheral role of CO, there is some evidence that neural CO plays an indirect role 
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in vasodilatation via signalling through the autonomic nervous system (Verma, Hirsch et 
al. 1993). 
 
 1.4.2.3 Anti-Inflammatory Effects 
CO has been shown to be associated with significant anti-inflammatory effects 
which have been demonstrated in both in vitro and in vivo studies. For example, in an in 
vitro model of sepsis, Otterbein (2000) stimulated macrophages with LPS which induced 
an increase in TNF-α and other pro-inflammatory cytokines (Otterbein, Bach et al. 2000). 
The exogenous administration of low-dose CO inhibited this pro-inflammatory response. 
Furthermore, CO also inhibited the expression of other pro-inflammatory cytokines, such 
as IL-1β and MIP-1β, while increasing the expression of IL-10, an anti-inflammatory 
cytokine.  
Beneficial effects of CO in relation to systemic inflammation have also been 
demonstrated in in vivo experiments. When examining the impact of I/R-induced 
systemic inflammatory response syndrome (SIRS), the exogenous administration of low-
dose CO was able to prevent liver and small intestine microvascular dysfunction (Ott, 
Scott et al. 2005, Scott, Cukiernik et al. 2009). In another study, Song et al. (2003) 
performed orthotopic lung transplant in rats, which showed severe intra-alveolar 
hemorrhage, a significant increase in inflammatory cellular infiltration and intravascular 
coagulation. The response, however, was significantly attenuated with the exposure to 
500ppm of CO; in these experiments, CO also downregulated pro-inflammatory genes 
such as MIP-1α and MIF (Song, Kubo et al. 2003). 
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1.4.2.4 Anti-Apoptotic Effects 
To date, there have been multiple in vivo and in vitro studies demonstrating the 
anti-apoptotic effects of CO. In an in vitro mouse model, TNF-α-induced apoptosis of 
endothelial cells and fibroblasts was reduced following exposure to CO (Petrache, 
Otterbein et al. 2000). As HO-1 protects endothelial cells (EC) from apoptosis, Brouard 
(2000) were able to demonstrate that blocking the enzyme activity of HO-1 with tin 
protoporphyrin (SnPPIX) leads to EC apoptosis. By exposing EC to exogenous CO, they 
were able to once again prevent apoptosis in the face of HO-1 inhibition. The findings 
demonstrated that the anti-apoptotic effects of HO-1 were mediated by CO and more 
specifically, by the activation of the p38 MAPK pathway (Brouard, Otterbein et al. 
2000).  
In vivo research, examining tissue injury following I/R, found that pre-treatment 
with low-dose exogenously administered CO also had anti-apoptotic effects (Ryter, Alam 
et al. 2006). In a study by Abe et al. (2017), the exposure of rat kidney grafts to oxidative 
stress in the presence and absence of high pressure CO found that CO significantly 
improved graft function and inhibited tubular apoptosis (Abe, Yazawa et al. 2017).  
 
1.4.3 Carbon Monoxide-Releasing Molecules (CO-RMs) 
CO gas is known to be non-reactive, not expensive and easily produced. Due to 
these properties, it became desirable to develop a set of compounds that could safely 
carry and deliver CO to biological systems and tissues, bypassing inhalation-associated 
COHb formation. Considering the known beneficial effects of HO and exogenous CO 
administration, and knowing that CO binds strongly to transition metals in organic 
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solvents, Motterlini et al. (2002), synthesized a novel class of transition metal carbonyls, 
capable of releasing CO on demand (Motterlini, Clark et al. 2002). These carbon 
monoxide-releasing molecules (CO-RMs) form carbonyl complexes, such as manganese 
decarbonyl and tricarbonyl-dichloro-ruthenium dimer, which can release CO upon 
activation. CO-RMs are, therefore, capable of delivering CO to the tissues in a controlled 
manner, without causing a dangerous increase in COHb formation (Motterlini, Clark et 
al. 2002). CO-RMs can thus be considered chemical delivery vehicles for CO.  
The first CO-RM to be synthesised was CORM-1 (formula [Mn2(CO)10]). It 
contains manganese at its centre, and is a rapid CO releaser (Motterlini 2007), but 
requires photo-activation, thereby limiting its use to in vitro protocols. The second CO-
RM synthesized was CORM-2 (formula [Ru(CO3Cl2)], containing a ruthenium metal 
dimer at its core. CORM-2 requires organic solvent (e.g. DMSO) for CO release also 
limiting its clinical use (Motterlini 2007). CORM-3 (formula [Ru(CO)3Cl(glycinate)]) 
was the first water-soluble ruthenium-based carbonyl that readily and rapidly releases CO 
under physiological conditions (Motterlini 2007), making it an attractive compound for 
clinical applications. The release of CO by CO-RMs has been validated 
spectroscopically, utilising the myoglobin-binding assay (conversion of myoglobin into 
carboxymyoglobin) and the biological and physiological effects of CO-RMs have been 
confirmed by numerous experiments (Motterlini 2007). 
 
1.4.4 Carbon Monoxide-Releasing Molecule-3 (CORM-3) 
CORM-3 is an equimolar CO releaser under physiological conditions. CORM-3 
has been shown to have beneficial vasodilatory properties in aortas (Foresti 2004), 
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positive ionotropic and anti-ischemic effect in cardiac and renal tissues (Musameh 2006; 
Sandouka, 2006), and to cause mesenteric vasodilatation in cirrhotic rats (Bolognesi 
2007). Furthermore, CORM-3 has been shown to have therapeutic potential in various 
inflammatory conditions, such as acute liver failure induced by lipopolysaccharide (LPS) 
(Yan, Yang et al. 2016), postmenopausal arthritis (Ibanez, Alcaraz et al. 2012) and also 
reduced tissue injury, inflammatory response and TNF-α levels in a rat model of 
hemorrhagic stroke (Yabluchanskiy, Sawle et al. 2012). The mechanism of action of 
CORM-3 is unclear, but it appears to regulate the production of TNF-α, fibrinogen/fibrin, 
cellular infiltration, ICAM-1 expression and the activation of transcription factors (NF-
κB, MAPK) (Kramkowski, Leszczynska et al. 2012). CORM-3 has also been shown to 
have direct bactericidal properties against bacteria such as Pseudomonas aeruginosa 
(Desmard, Davidge et al. 2009).  
CO-RMs and CORM-3 have been shown to have various positive therapeutic 
effects. In a rodent model of CS, the administration of CORM-3 at the time of fasciotomy 
was associated with a decrease in leukocyte activation, systemic TNF-α release, and 
diminished tissue injury, while improving microvascular perfusion (Lawendy et al, 
2014). In a rat model of I/R injury following kidney transplantation, pre-treatment of 
donor grafts with CORM-3 was shown to improve recipient survival, graft survival and 
decrease serum creatinine levels compared to control (Caumartin, Stephen et al. 2011). A 
study by Bihari et al., (2017), looking at I/R injury in a hind limb rat model, found that 
treatment with CORM-3 improved tissue perfusion while decreasing tissue injury and 
inflammatory activation (Bihari, Cepinskas et al. 2017).   
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1.4.5  CORM-3 in Human CS 
CORM-3 has never been tested in human patients. While the results of animal 
studies employing CORM-3 as a therapeutic/interventional agent in various inflammatory 
conditions look promising, CORM-3 would have to be thoroughly examined before 
applying it towards human clinical pathology. The first step would be testing CORM-3 in 
a relevant, reliable and reproducible in vitro model, such as that employing human 
vascular endothelial cells (HUVECs). 
Jaffe et al. (1973) described the process of isolating HUVECs from umbilical 
cords by collagenase digestion, and used electron microscopy to demonstrate their 
monolayered growth (Jaffe, Nachman et al. 1973).  Since then, HUVECs have been used 
extensively to study various pathological developments, such as the inflammatory 
processes underlying diabetes and atherosclerosis (Onat, Brillon et al. 2011). In a study 
by Caumartin et al. (2011), investigators pre-treated cultured human umbilical vein 
endothelial cells with CORM-2 and found altered inflammatory state, coupled with 
reduced levels of cytokines, ROS, and pro-inflammatory transcription factors (Caumartin, 
Stephen et al. 2011). In addition, in an in vitro model of CS, incubating HUVECs with 
serum isolated from CS patients, Bihari et al (2017) found that application of CORM-3 
significantly diminished the CS-induced HUVECs monolayer breakdown, ROS 
production, apoptosis, leukocyte adhesion and transmigration (Bihari, Cepinskas et al. 
2017). 
 
	 49 
1.5 AIM OF THE THESIS 
Significant gains have been made towards understanding the pathophysiology of 
CS, yet much remains to be determined. Currently, surgical fascial decompression is the 
only definitive treatment for CS, with current pharmacological therapies limited as 
adjuncts to surgery. In order to deliver effective surgical and medical therapies, the 
pathophysiological basis for the underlying condition and treatments needs to be better 
understood. 
The purpose of this thesis is to further expand upon the human in vitro model of 
CS, developed by Bihari et al (2017), using elevation of hydrostatic pressure (EHP). 
Previous experiments have demonstrated that a significant level of microvascular injury 
and dysfunction develops in response to CS, as demonstrated by the loss of continuously 
perfused capillaries, elevated tissue injury and a significant degree of tissue 
inflammation.	Unlike complete ischemia, however, CS appears to cause myonecrosis in 
the face of patent vessels, implicating leukocytes as playing a primary role in both 
microvascular and parenchymal injury during CS.	 Activated leukocytes are a major 
source of inflammatory cytokines; as such, systemic neutralization of these was able to 
diminish the severity of observed tissue injury, however it was unable to restore the 
proper microvascular perfusion (Donohoe 2015). This would suggest that the elevated 
tissue pressure itself contributes a significant amount of damage to the muscle 
microcirculation (i.e. inflammation is not the only driving force behind the CS 
pathophysiology), creating physical changes within the endothelial monolayer of muscle 
blood vessels that lead to microvascular compromise.  
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In vitro modelling of CS allows us not only to explore the underlying 
pathophysiology in a mechanistic manner, but also permits interventions that are 
currently not possible (or unethical) in humans. Thus, the ultimate goal of this thesis is to 
further our understanding of CS pathophysiology, and to develop a safe medical adjunct 
(or standalone therapy) for patients presenting with CS, avoiding (or at the least, 
minimizing) the potential devastating complications of this complex condition. 
This thesis is organized into four chapters. The general introduction and historical 
review of CS, highlighting the advances in our understanding of diagnosis (both clinical 
and through objective monitoring), therapeutic approaches and pathophysiology 
(describing the microvascular dysfunction, inflammation, as well as important differences 
between CS and ischemia-reperfusion injury), which have been made over the past 140 
years, are summarized in Chapter 1. We introduce CO and its potential beneficial role by 
underlining its biological effects, and the recent development of carbon monoxide-
releasing molecules. 
The response of human vascular endothelial cells (HUVECs) to elevated 
hydrostatic pressure, as an in vitro model of CS, is described in Chapter 2. Outcome 
measures included changes to monolayer structure, endothelial activation (measured by 
assessing leukocyte adhesion to the endothelium), production of ROS and apoptosis. 
The effects of CORM-3 on the magnitude of response of HUVECs to EHP are 
described in Chapter 3. Relative contribution of EHP versus inflammatory mediators 
(cytokines) was also assessed. 
Finally, conclusions, study limitations and future directions are addressed in 
Chapter 4 (General Discussion). 
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CHAPTER 2. ELEVATED HYDROSTATIC PRESSURE ALTERS 
ENDOTHELIAL CELLS IN AN IN VITRO MODEL OF COMPARTMENT 
SYNDROME  
 
2.1 INTRODUCTION 
Compartment syndrome (CS) is a true medical and surgical emergency, with 
potential devastating consequences, caused by an elevation in pressure within a closed 
osseofascial compartment (Matsen, Winquist et al. 1980). The intercompartmental fascia 
is unyielding (Gratz 1931) and as such, individual compartments have limited ability to 
expand; this makes them vulnerable to small increases in intracompartmental pressure 
(ICP) or decreases in volume. The increase in pressure within the closed compartment 
leads to microvascular dysfunction and compromise, thereby creating an ischemic 
environment within the compartment. This limits oxygen and nutrient delivery, as well as 
gas exchange, resulting in cellular anoxia, muscle necrosis and eventual cell death 
(Sheridan and Matsen 1975, Whitesides, Haney et al. 1975, Mubarak, Owen et al. 1978, 
Rorabeck and Clarke 1978, Matsen 1980, Hartsock, O'Farrell et al. 1998).  
The importance of various inflammatory processes is increasingly being 
recognized as contributing to the pathophysiology of CS (Lawendy, Sanders et al. 2011, 
Lawendy, Bihari et al. 2015). The role of activated leukocytes and the direct negative 
impact they may have on capillary perfusion, including intravascular protein leakage, 
leading to tissue edema and parenchymal injury is progressively being documented in the 
pathophysiology of CS (Kurose, Anderson et al. 1994, Forbes, Carson et al. 1995, Forbes, 
Harris et al. 1996, Harris and Skalak 1996).  
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Currently, the only effective treatment for CS is surgical fasciotomy (Olson and 
Glasgow 2005), with few other treatment modalities or adjuncts. Although fasciotomy is 
effective, it is associated with significant (and not infrequent) complications. Some 
adjunctive therapies have shown limited but promising potential in animal models 
(Manjoo, Sanders et al. 2010, Lawendy, Bihari et al. 2014), but their use is hindered by 
both the lack of a thorough understanding of the pathophysiological basis of CS injury, 
and the lack of human models on which to develop research protocols and treatments. 
The purpose of this study was to attempt to translate the recent progress which has been 
made in animal studies to human subjects. To accomplish this, we developed an in vitro 
model of CS using human vascular endothelial cells and elevated hydrostatic pressure.  
We hypothesised that elevation of hydrostatic pressure to 30mmHg would have a 
detrimental effect on the HUVECs, producing significant changes in the endothelial 
monolayer, thus contributing to the breakdown of endothelial barrier. The ultimate and 
hopefully eventual goal of the study is the development of a safe pharmacologic 
adjunctive treatment for CS, which would reduce the morbidity and disability in patients. 
 
 
2.2 MATERIALS AND METHODS 
2.2.1 Reagents 
Medium-199 (M199), fetal bovine serum, penicillin, streptomycin and Dulbecco’s 
PBS (DPBS) (pH 7.4) were purchased from Invitrogen Canada (Life Technologies Inc., 
Burlington, ON). Dihydrorhodamine (DHR)-123 was obtained from Molecular Probes 
Inc. (Eugene, OR). 
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2.2.2 Cells 
2.2.2.1 HUVECs 
Human vascular endothelial cells (HUVECs) were isolated from human umbilical 
veins by collagenase treatment, as previously described (Yoshida, Granger et al. 1992, 
Cepinskas, Sandig et al. 1999, Cepinskas, Savickiene et al. 2003). Briefly, under sterile 
conditions, an umbilical cord was washed with PBS; a three-way stopcock was inserted 
into the umbilical vein and secured into position.  Culture medium was then flushed 
through the cord to remove soft tissue and blood clots, followed by an injection of 
collagenase and incubation at room temperature for 30 minutes.  The collected fluid and 
medium was centrifuged, discarding the supernatant while resuspending the pellet in the 
fresh medium.  
The HUVECs were plated on parallel-flow multichannel slides (ibidi µ-Slides VI 
0.4) in M199 supplemented with 10% heat-inactivated fetal bovine serum, antibiotics 
(100i.u./ml penicillin, 100µg/ml streptomycin and 0.125µg/ml amphotericin B), and 
incubated at 37°C in a humidified atmosphere with 5% CO2. Cell were grown to 
confluence. HUVECs at passages 1-3 were used for all of the experiments. 
 
2.2.2.2 Neutrophils 
Human neutrophils, i.e. polymorphonuclear cells (PMNs), were isolated from the 
venous blood of healthy adults by 1% Dextran (Sigma, Mississauga, ON) sedimentation 
and gradient separation on Histopaque-1077 (Sigma, Mississauga, ON), followed by the 
lysing of red blood cells with ammonium chloride solution, as previously described 
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(Yoshida, Granger et al. 1992, Kuhns, Long Priel et al. 2015). Isolated leukocytes were 
reconstituted in 0.1M phosphate buffered saline (PBS), pH 7.4, adjusting the buffer 
volume to achieve the concentration of 1x109 leukocytes/ml. PMN viability was 
confirmed by Trypan blue dye exclusion test. This procedure yielded a PMN population 
that was 95–98% viable.  
 
2.2.3 In vitro Pressure Model of CS 
HUVECs were subjected to varied hydrostatic pressures (0mmHg and 30mmHg) 
for 4 hours via a gravity-fed system, closed off with 3-way stopcocks. The system was 
connected to a compartment pressure monitor (Synthes, Westchester, PA) to ensure 
constant and uniform pressures (Figure 2.1). Both pressure groups were compared to a 
control which was exposed to normal room pressure. The 0mmHg (i.e. sham group) was 
included, to control for the experimental pressure set-up. All experimentation was 
performed in an incubator, at 37°C. All experiments were repeated five times, on 
different days, to account for any variability in ambient conditions. 
 
2.2.4 Cellular Morphology 
Morphological changes in the cell shape and integrity, as well as the integrity of 
intercellular junctions were qualitatively assessed through F-actin and VE-Cadherin 
immunostaining, respectively. Confluent cells were exposed to elevated hydrostatic 
pressure (EHP) for 4 hours, followed by fixation in 3.7% formalin, washing three times 
in 0.1M PBS, pH7.4, and solubilisation with 0.1% Triton X-100 in PBS for 15min. Cells 
were then subjected to a standard immunostaining protocol for either F-actin (phalloidin 
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staining) or VE-cadherin. Both Alexa Fluor 594 and Texas Red fluorochromes were 
visualized with Zeiss Axiophot epifluorescence microscope using excitation/emission 
wavelengths of 590/617nm, while bisbenzimide was visualized with wavelengths of 
343/383nm. 
 
2.2.4.1 F-actin Staining 
Slides were incubated with 1% bovine serum albumin for 30min, followed by 
6.6µM Alexa Fluor 598-labelled falloidin (F-actin stain) (Thermo Fisher Scientific, 
Mississauga, ON) for 1 hour. After washing with PBS three times, slides were 
coverslipped with fluorescence mounting medium (Vectashield, Vector Labs, 
Mississauga, ON). 
 
2.2.4.2 VE-cadherin Staining 
  Slides were incubated in 10% normal goat serum for 1 hour. After washing with 
0.1M PBS, they were incubated with a polyclonal VE-cadherin antibody (Santa Cruz 
Biotechnology Inc., Mississauga, ON) at 1:100 dilution for 2 hours. Slides were then 
washed three times in PBS and incubated with goat-anti-mouse IgG, conjugated with 
Texas Red, at 1:1000 dilution for 1 hour. Slides were then washed with PBS three times. 
To visualize cell nuclei, slides were counterstained with Hoechst 33342 dye 
(bisbenzimide) for 5 minutes.  Following three PBS washes, cells were then coverslipped 
with Vectashield and visualized by fluorescence illumination.  
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Figure 2.1 The experimental setup for the elevation of hydrostatic pressure 
(EHP) in the endothelial cells as an in vitro model of CS. HUVECs 
were plated on multichannel slides and exposed to culture medium of 
varied hydrostatic pressures via a gravity-fed system, with the system 
connected to a pressure monitor. 
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2.2.5 Reactive Oxygen Species (ROS) Production 
The production of ROS in HUVECs was measured by intracellular oxidation of 
dihydrorhodamine-123 (DHR-123), a pan-oxidant-sensitive fluorochrome, as previously 
described (Mizuguchi, Stephen et al. 2009, Bihari, Cepinskas et al. 2017). DHR-123 is an 
uncharged and nonfluorescent reactive oxygen species (ROS) indicator that can passively 
diffuse across membranes, where it is oxidized to cationic rhodamine-123 localizing in 
the mitochondria and exhibiting green fluorescence. Briefly, HUVECs (2.5x105 cells), 
grown to confluence, were loaded with DHR-123 (10µM) for 45min. Following a wash 
with normal M199, the cells were then subjected to elevation of hydrostatic pressure 
(EHP) for 4 hours, with either 0 mmHg or 30 mmHg. Following this, the cells were 
washed with PBS, lysed in 0.5% CHAPS buffer and analysed spectrofluorometrically 
(FR-1501 spectrofluorometer, Shimadzu) at excitation/emission wavelengths of 
495/523nm. Protein concentration in the cell lysate was assessed by DC protein assay 
(BioRad, Mississauga, ON). ROS production was expressed as DHR-123 fluorescence 
intensity (FI) per mg protein.  
 
2.2.6 Quantification of Apoptosis 
HUVECs were subjected to EHP of 30mmHg or 0mmHg for 4 hours, and the 
level of the activation of active caspases was assessed by FAM-FLICA poly caspase 
apoptosis kit (Immunochemistry Technologies, LLC), as per manufacturer’s instructions. 
Briefly, cells were incubated with FAM-FLICA poly caspase reagent for one hour at 
37°C, washed, detached from the slides (0.025% Trypsin in M199), plated on Lumitrac 
96-well black plates Greiner Bio-One) and immediately assessed for fluorescence using 
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Victor-3 plate reader (Perkin-Elmer), at excitation/emission wavelengths of 
480nm/530nm. Levels of apoptosis were expressed as relative fluorescence units (RFU) 
(i.e. fluorescence intensity/104). 
 
2.2.7 Leukocyte (PMN) Activation – Adhesion 
HUVECs grown on the parallel-flow perfusion microslides (µ-slide VI 0.4; ibidi, 
Madison, WI) were subjected to EHP of 30mmHg or 0mmHg for 4 hours. Microslides 
with HUVECs were then placed into an air-heated chamber (37°C) attached to an 
inverted phase-contrast microscope (Diaphot 300, Nikon). Following the 10min wash 
with M199 at a shear stress of 1dyn/cm2 using syringe pump (Harvard Apparatus, St. 
Laurent, QC), PMNs (1x106/ml) isolated from healthy adults were added to the perfusion 
medium and the perfusion was continued for 15 minutes at the same shear stress. PMN-
HUVECs adhesive interactions were captured in six random fields of view (10s/field) 
with a digital CCD camera (Sony Corp., Japan) connected to a computer, and analyzed 
offline. Adhesion was defined as PMNs that remained stationary for at least 10s. PMN 
adhesion was expressed as a number of PMN/mm2. 
 
2.2.8 Statistical Analysis 
All parameters were expressed as means ± standard error of the mean (SEM), and 
analyzed using one-way analysis of variance (ANOVA) (GraphPad Prism, v. 7.0, San 
Diego, CA), with Bonferroni post-hoc test as needed. p<0.05 was considered statistically 
significant. 
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2.3 RESULTS 
2.3.1 Structural Changes to Endothelium Due to EHP 
 Exposure of HUVECs to EHP of 30mmHg produced marked changes in F-actin 
and VE-cadherin staining (Figure 2.2). Sustained EHP of 30mmHg led to prominent 
stress fiber formation, as indicated by the significant increase in phalloidin labelling (a 
specific marker of F-actin). Junctional VE-cadherin staining pattern was also 
significantly altered, indicating gap formation within the endothelial monolayer. EHP 
maintained at 0mmHg, however, did not result in any changes to F-actin or VE-cadherin 
staining, both of which remained virtually identical to those seen in control cells. 
 
2.3.2 ROS Production 
Exposure of HUVECs to EHP of 30mmHg for 4 hours induced a significant 
increase in the production of ROS within the endothelial cells, as shown in Figure 2.3. 
DHR-123 fluorescence intensity increased from 325.0±20.1 FI/mg protein in control and 
340.1±38.0 FI/mg protein in 0mmHg to 556.9±71.4 FI/mg protein in 30mmHg group 
(p<0.05).  
 
2.3.3 Apoptosis 
Elevation of hydrostatic pressure to 30mmHg led to a significant increase in the 
activation of caspases, as shown in Figure 2.4. The caspases activation increased from 
1.7±0.5 RFI in control and 1.6±0.4 RFI in the 0mmHg groups to 4.0±0.7 RFI in 30mmHg 
group (p<0.05). 
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Figure 2.2 The effect of EHP on the expression of F-actin and VE-cadherin in an 
in vitro model of CS. CS stimulus, in the form of a sustained EHP at 
30mmHg, led to an increase in stress fiber formation and changes to 
junctional staining pattern of HUVECs. 
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Figure 2.3 The effect of EHP on the level of oxidative stress within the 
endothelial cells in an in vitro model of CS. CS stimulus, in the form of 
sustained EHP at 30mmHg for 4 hours, led to a significant increase in 
reactive oxygen species formation within HUVECs. (One-way ANOVA, 
*p<0.05; N=5 per group). 
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Figure 2.4 The effect of EHP on level of apoptosis within the endothelial cells in 
an in vitro model of CS. CS stimulus, in the form of sustained EHP at 
30mmHg for 4 hours, led to a significant increase in the activity of 
caspases within HUVECs. (One-way ANOVA, *p<0.05; N=5 per group). 
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2.3.4 PMN Adhesion 
Elevation of hydrostatic pressure to 30mmHg resulted in a marked increase in 
PMN activation, as demonstrated by an increase in PMN adhesion to HUVECs 
monolayer under the conditions of flow. Adhesion increased from 4.0±1.5 PMNs/0.1mm2 
in the control and 3.8±1.2 PMNs/0.1mm2 in the 0mmHg groups to 12.2±1.7 
PMNs//0.1mm2 in the EHP of 30mmHg group (p<0.05) (Figure 2.5). 
 
 
2.4 DISCUSSION 
CS is associated with a complex and often times confusing diagnostic picture, 
limited therapeutic options, significant complications and, unfortunately, significant 
patient disability (Giannoudis, Nicolopoulos et al. 2002). While certain non-operative 
adjuncts such as NSAIDs, tissue ultrafiltration and hyperbaric oxygen therapy have 
shown therapeutic potential in certain animal models and small human case series 
(Manjoo, Sanders et al. 2010, Lawendy, Bihari et al. 2014), their clinical use has been 
limited by a lack of understanding of the pathophysiology underlying both CS and the 
individual therapies as well as the lack of an effective human model on which to test 
therapeutic treatments. 
In the present study, we attempted to mimic the CS conditions in vitro by 
subjecting human vascular endothelial cells to elevated hydrostatic pressure (the CS-
relevant stimulus), directly assessing cellular response, while attempting to clarify the 
role in which EHP contributes to the endothelial activation and pro-inflammatory 
potential of CS. To our knowledge, this is the first study to model CS in cell culture using  
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Figure 2.5. The effect of EHP on the endothelial cell activation in an in vitro 
model of CS. CS stimulus, in the form of sustained EHP at 30mmHg for 4 
hours, led to a significant endothelial activation, as measured by an 
increase in PMN leukocyte adhesion to HUVECs. (One-way ANOVA, 
*p<0.05; N=5 per group). 
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EHP as a CS-relevant stimulus. The primary goal of these studies is to further our 
understanding of the pathophysiology leading to CS, as well as to allow for the 
development and testing of potential interventions currently not possible (or even 
unethical) in human subjects. 
 CS is comprised of a complex cascade of intracellular and extracellular events, 
eventually creating a pro-inflammatory milieu, with the subsequent activation of vascular 
endothelial cells and leukocytes. This leads to impaired cell-to-cell integrity, increased 
vascular permeability, leukocyte extravasation and the formation of interstitial edema 
(Sabido, Milazzo et al. 1994). The cellular and molecular basis underlying the 
parenchymal injury/organ dysfunction associated with CS are also poorly understood. In 
addition, there are no studies using human material to assess the health of vascular 
endothelial cells in response to stimulation with a CS-like stimulus. 
In the current study, exposure of HUVECs to EHP led to a rearrangement of 
stress fibers and a breakdown of endothelial barrier, as evidenced by changes in F-actin 
and VE-cadherin expression (Figure 2.2).  This is in keeping with previous research 
which found that EHP led to changes in endothelial cell morphology (Acevedo, Bowser 
et al. 1993). Furthermore, alterations in cellular structure in response to EHP are not seen 
to occur only in endothelial cells. In chondrocytes, EHP leads to F-actin thinning and 
disorganization, as well as a decrease in cell stiffness (Cao, Xia et al. 2015). Furthermore, 
Tokuda (2009) were able to show that the exposure of epithelial cells to EHP induced 
dynamic changes in cell height, actin structure and intercellular junctions (Tokuda, 
Miyazaki et al. 2009). Finally, Ohashi et al. (2007) found lower levels of VE-cadherin 
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and changes to cell structure, as well as loss of contact inhibition in bovine aortic 
endothelial cells exposed to EHP (Ohashi, Sugaya et al. 2007).  
Under normal circumstances, the intact endothelium provides a semi-selective 
barrier between the vessel lumen and the interstitial tissue, controlling the passage of 
fluid, proteins, leukocytes and other material between the blood and the interstitium. 
When the endothelium is subjected to cellular stress and inflammation, it experiences an 
increase in permeability, eventually leading to tissue edema. This also creates non-
perfused segments within the capillary system, further contributing to ischemia and 
microvascular dysfunction (Sabido, Milazzo et al. 1994). A study by Kataoka et al. 
(1998) found that subconfluent bovine aortic endothelial cells responded differently to 
shear stress than confluent cells, suggesting that cell shape change is dependent on cell to 
cell contact with neighbouring cells (Kataoka, Ujita et al. 1998). It has been postulated 
that changes in hydrostatic pressure may enhance the synthesis of VEGF by the 
endothelial cells, leading to dephosphorylation of catenins and a decrease in the 
formation of adherens junctions dependent on VE-cadherin (Ohashi, Sugaya et al. 2007). 
A study by Martin (2005) in renal cell lines subjected to pathological hydrostatic 
pressures found that EHP leads to shortening of actin fiber length (Martin, Brown et al. 
2005). Previously, Ingber proposed the “tensegrity” model, which stipulates that different 
mechanical forces applied to a cell will be transmitted by actin filaments to proteins, like 
integrins, which anchor the cell to the extracellular matrix; these forces can cause 
reorganization of integrins into a different pattern, in order to resist those forces (Ingber 
1993). In the context of CS, it is plausible to assume that the elevation of 
intracompartmental pressure results in EHP, directly producing changes in the endothelial 
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cell cytoskeleton (e.g. F-actin assembly) and associated adherens junction protein 
function (e.g. VE-cadherin, β-catenin) (Corada, Liao et al. 2001, Giannotta, Trani et al. 
2013), thus further contributing to the breakdown of endothelial barrier. 
When endothelial cells were subjected to sustained EHP, a significant increase in 
intracellular production of ROS was observed (Figure 2.3). Increased ROS production is 
most likely due, at least in part, to changes in the mitochondrial respiratory chain. This is 
in agreement with previous research in deep dive physiology, suggesting that elevated 
hydrostatic pressure has direct impact on the mitochondrial respiratory chain or the inner 
mitochondrial membrane (Wang, Guerrero et al. 2015). Furthermore, it can also be 
surmised that an increase in ROS, as a result of EHP, will trigger downstream signalling, 
stimulating inflammation (Toyokuni 1999). Acute inflammatory reactions, such as those 
seen in ischemia-reperfusion and CS, are mediated by a number of pro-inflammatory 
cytokines (Donohoe 2015). Cytokines are known to induce oxidative stress, leading to 
cellular membrane compromise, changes in internal protein structure and downstream 
effects on enzymes (Sprague and Khalil 2009). Interestingly, previous research has 
shown that EHP leads to an upregulation of cytokine levels in various cell types, such as 
periodontal ligament cells (Yamamoto, Kita et al. 2006), bladder smooth muscle cells 
(Liang, Xin et al. 2016), mesenchymal stem cells (Becquart, Cruel et al. 2016), human 
tumour cells (Fucikova, Moserova et al. 2014) and human chondrocytes (Fioravanti, 
Moretti et al. 2007). It has been demonstrated, using vascular endothelial cells, that an 
increase in intraluminal pressure leads to an induction of nuclear factor кB (NF- кB) 
(Lemarie, Esposito et al. 2003), a transcription factor controlling the expression of 
various cytokines, chemokines and adhesion molecules (De Martin, Hoeth et al. 2000). In 
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addition, application of cyclic hydrostatic pressure to HUVECs found an increase in 
CD95, a member of the TNF receptor family that is known to induce apoptosis, as well as 
elicit cytokine release (Hasel, Durr et al. 2005). 
In addition to activation of the pro-inflammatory pathways, ROS also play a 
critical role in activation of various caspases (e.g. caspase-3), cytosolic enzymes 
responsible for the induction of cell apoptosis (Elmore 2007). In the current study, EHP 
resulted in an increase in endothelial apoptosis (Figure 2.4). This is consistent with the 
observations of Ju et al. (2009), who found that an exposure of cultured retinal ganglion 
cells to EHP of 30mmHg led to mitochondrial fissuring and increased release of 
cytochrome c into the cytoplasm, thus activating caspase-3 (Ju, Kim et al. 2009). 
Additionally, Lee et al. (2010) also found an increase in intracellular calcium elevation 
followed by elevated caspase-3/7 activation, suggesting that calcium, through its impact 
on ion channel activity and water efflux, is responsible for signalling the onset of the 
apoptotic cell changes  (Lee, Lu et al. 2010). Given that CS produces a strong pro-oxidant 
and pro-inflammatory environment (characterized by the presence of ROS and 
inflammatory cytokines, particularly TNF-α (Lawendy, Bihari et al. 2014, Lawendy, 
Bihari et al. 2015)) it is plausible to assume that, in response to EHP, both intrinsic 
(mitochondria/cytochrome c-mediated) and extrinsic (TNF-α receptor-mediated) 
apoptotic pathways would be activated (Elmore 2007).   
One of the essential features of CS appears to be the production of pro-
inflammatory mediators, and subsequent infiltration of activated leukocytes, particularly, 
neutrophils, into the affected tissue (Sadasivan, Carden et al. 1997, Lawendy, Sanders et 
al. 2011). Leukocyte activation, recruitment and accumulation at the site of injury are 
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normal host responses intended to assist with pathogen and dead cell removal. However, 
in pathological situations, response to cellular stress, the accumulation of PMNs and 
subsequent production of cytotoxic ROS, coupled with a release of proteolytic enzymes 
can overwhelm the system, thus contribute to the parenchymal damage. Activated 
leukocytes, and the pro-inflammatory state they create will impair the viability of 
surrounding cells (Toyokuni 1999), further contributing to tissue injury and organ 
dysfunction. 
 Recent research indicates that the pathophysiology underlying CS is, at least in 
part, driven by ischemia-reperfusion injury. The cellular and clinical effects of complete 
ischemia on the skeletal muscle are well documented (Harman 1948, Strock and Majno 
1969, Labbe, Lindsay et al. 1987, Belkin, Brown et al. 1988, Lindsay, Liauw et al. 1990, 
Hickey, Hurley et al. 1992, Sabido, Milazzo et al. 1994): ischemia  creates a shift in 
cellular metabolism towards a mainly oxidative mode, while restoration of previously 
ischemic tissue will produce a pro-inflammatory state (Gute, Ishida et al. 1998, Gillani, 
Cao et al. 2012), characterized by an influx of activated leukocytes from the circulation 
into the surrounding tissues (Hernandez, Grisham et al. 1987, Kubes, Suzuki et al. 1990, 
Schlag, Harris et al. 2001). PMN recruitment involves a series of complex and well-
coordinated cell-to-cell interactions by differential expression of various adhesion 
molecules on both the endothelium and the leukocyte; these include selectin-mediated 
PMN rolling, integrin-mediated firm adhesion, followed by PECAM-1-, CD99- and 
JAM-mediated transmigration across the endothelial barrier into the interstitial space 
(Ley, Laudanna et al. 2007). Furthermore, activated leukocytes themselves are also a 
significant source of ROS and proteolytic enzymes, contributing to interstitial edema 
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(Sexton, Korthuis et al. 1990, Forbes, Carson et al. 1995, Rubin, Romaschin et al. 1996, 
Kurose, Argenbright et al. 1997, Gute, Ishida et al. 1998). In the context of CS, the fluid 
accumulation leads to a significant increase in the interstitial pressure, further  
compressing the neighbouring capillaries and exacerbating the perfusion deficit 
(Lawendy, Sanders et al. 2011).  
In the current study, EHP applied to endothelial cells led to a significant increase 
in leukocyte adhesion (Figure 2.5), a key feature of leukocyte and/or vascular endothelial 
cell inflammatory activation (Butcher 1991, Ley, Laudanna et al. 2007). These results 
suggest that EHP not only induces ROS production, apoptosis and cytokine release, but it 
also has the potential to induce endothelial cell activation directly. It is plausible to 
assume that changes in hydrostatic pressure will cause changes in the expression of 
adhesion molecules on the vascular endothelium (e.g. P-selectin, E-selectin, ICAM-1, 
VCAM-1), allowing them to interact with their ligands on the PMNs (e.g. L-selectin, 
sialyl-LewisX, β2 integrins). 
 In summary, this is the first study demonstrating the impact of increased 
hydrostatic pressure on the human vascular endothelial cells in an in vitro model of CS. It 
represents the first step in an attempt to further elaborate to mechanisms driving the 
pathophysiology of CS.	
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CHAPTER 3.    CARBON MONOXIDE-RELEASING MOLECULE-3 (CORM-3) 
IMPROVES ENDOTHELIAL CELL DYSFUNCTION IN AN IN VITRO MODEL 
OF COMPARTMENT SYNDROME 
 
 
3.1 INTRODUCTION 
Compartment syndrome (CS) is a devastating complication of musculoskeletal 
trauma. CS occurs following a rise in intra-compartmental pressure within a closed 
osseofascial compartment. If unrecognized, and/or untreated, the condition will lead to a 
muscle-threatening and limb-threatening ischemia (Whitesides, Haney et al. 1975, 
Matsen, Winquist et al. 1980, Mubarak and Hargens 1983). Currently, the only definitive 
treatment is surgical fasciotomy, with the goal of fully decompressing all of the affected 
compartments (Eaton and Green 1972, Rorabeck 1984). Fasciotomy must be carried out 
within 6-8 hours of CS onset, or the resulting tissue damage, neurovascular injury and 
limb ischemia become permanent. 
The increase in compartmental pressure seen in CS leads to microcirculatory 
compromise restricting oxygen and nutrient delivery to the tissues,  thus leading to 
cellular anoxia, tissue necrosis and limb dysfunction (Whitesides, Haney et al. 1975, 
Hargens, Schmidt et al. 1981). However, unlike situations of complete ischemia, CS 
causes tissue necrosis in the presence of patent vessels. Although the full 
pathophysiology of CS has not been fully elucidated, the contribution of inflammation is 
increasingly being recognized as one of the important driving forces (Lawendy, Sanders 
et al. 2011, Bihari, Cepinskas et al. 2015). Lawendy et al (2011) and others (Sadasivan, 
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Carden et al. 1997, Kalns, Cox et al. 2011) have shown that leukocytes appear to play an 
important role in producing both the microvascular and the parenchymal injury seen in 
CS. 
Unfortunately, there are currently a limited number of effective therapeutic 
options when it comes to treating CS. Recently, carbon monoxide (CO), a byproduct of 
heme oxygenase (HO) activity, has been shown to improve microvascular perfusion, and 
to convey anti-inflammatory benefits during systemic inflammation. The exogenous 
administration of CO via inhalation leads to increased carboxyhemoglobin (COHb) 
levels, toxic to the host in the form of CO poisoning. However, transitional metal 
carbonyls, such as CO-releasing molecules (CO-RMs), have been synthesized and can be 
used experimentally, to deliver CO to the tissues in a controlled manner without 
significantly raising COHb levels (Motterlini, Clark et al. 2002, Clark, Naughton et al. 
2003). While most CO-RMs are soluble in organic solvents, carbon monoxide-releasing 
molecule-3 (CORM-3) is water soluble (Motterlini and Otterbein 2010), making it an 
ideal choice for clinical applications. In a rodent and porcine models of CS, the 
application of CORM-3 at the time of surgical fasciotomy was shown to diminish tissue 
injury, leukocyte activation and block the systemic release of TNF-α, a very potent pro-
inflammatory cytokine (Lawendy, Bihari et al. 2014, Bihari, Cepinskas et al. 2015). 
While these results are promising, more experimental testing is required before CORM-3 
could be used as a therapeutic agent in human patients. Furthermore, the underlying 
mechanism and the actual beneficial effects of CORM-3 protection, as well as its 
potential side effects still remain to be elucidated. 
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The primary purpose of this study was to provide a transition between the 
previous animal studies and future testing of CO on human subjects. We attempted to 
evaluate the relative contribution of both elevated tissue pressure and inflammation to the 
pathophysiology of CS, as well as to examine the beneficial effect of CORM-3-derived 
CO. To this end, we used two clinically relevant in vitro models of CS: elevation of 
hydrostatic pressure (EHP) and the exposure of human vascular endothelial cells 
(HUVECs) to a cytokine/chemokine cocktail (representing the serum levels of 
inflammatory mediators previously detected in our experimental animal models of CS) 
(“CS cocktail”) (Donohoe 2015). We hypothesized that the exposure of endothelial 
monolayer to inflammatory cytokines/chemokines will result in similar response to that 
obtained by the application of EHP, characterized by the activation of the endothelium, 
endothelial barrier breakdown and dysfunction. In addition, given that CORM-3 appears 
to provide beneficial effects in various animal models (Bihari 2017), we surmised that we 
could replicate these results in vitro, and also explore some of the mechanisms through 
which CORM-3 protects the endothelium.  The ultimate goal of this research is the 
development of a safe pharmacologic adjunct therapy aimed at human patients with CS, 
in order to reduce the morbidity and disability resulting from this devastating condition. 
 
 
3.2 MATERIALS AND METHODS 
3.2.1 Reagents 
Medium-199 (M199), fetal bovine serum, penicillin, streptomycin and Dulbecco’s 
PBS (DPBS) (pH 7.4) were purchased from Invitrogen Canada (Life Technologies Inc., 
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Burlington, ON). Dihydrorhodamine (DHR)-123 was obtained from Molecular Probes 
Inc. (Eugene, OR). Human recombinant TNF-α, IL-1β and GRO were purchased from 
Invitrogen Canada (Life Technologies Inc., Burlington, ON). A water-soluble CORM-3 
(tricarbonylchloro-glycinate-ruthenium(II), [Ru(CO)3Cl-glycinate]; molecular weight 295 
gmol-1) was synthesized by this laboratory (Mizuguchi, Stephen et al. 2009), in 
accordance with the previously-published method (Motterlini, Clark et al. 2002).  
CORM-3 (100µM stock solution) was always prepared fresh by dissolving CORM-3 in 
M199 just prior to use. Inactive CORM-3 (iCORM-3) was generated by leaving CORM-
3 solution for 72hrs at room temperature, to liberate all CO from the molecule, as 
previously described (Clark, Naughton et al. 2003). 
 
3.2.2 Cells 
Human vascular endothelial cells (HUVECs), isolated from human umbilical 
veins by collagenase treatment (Cepinskas, Savickiene et al. 2003), were grown to 
confluence on fibronectin-coated cellware (12-well plates, transwell inserts with 1µm 
diameter pores, 96-well plates and parallel-flow perfusion microslides). HUVECs at 
passages 1-3 were used for all of the experiments. 
Human neutrophils (PMNs) were isolated from the venous blood of healthy adults 
by 1% Dextran (Sigma, Mississauga, ON) sedimentation and gradient separation on 
Histopaque-1077 (Sigma, Mississauga, ON), as previously described (Kuhns, Long Priel 
et al. 2015). PMN viability was confirmed by Trypan blue dye exclusion test. 
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3.2.3 In vitro Models of CS 
To assess the relative contribution of physical tissue pressure elevation versus 
pro-inflammatory conditions to the severity of tissue injury seen in CS, two different 
models were employed: elevation of hydrostatic pressure (EHP), and cytokine/chemokine 
cocktail stimulation. 
 
3.2.3.1 Elevation of Hydrostatic Pressure 
Confluent HUVECs were exposed to EHP of 30mmHg, obtained via a gravity-fed 
system, for 6 hours, as previously described (Chapter 2, Figure 2.1). The system was 
connected to a compartment pressure monitor (Synthes, Westchester, PA) to ensure that 
constant and uniform pressures were obtained for the duration of the experiment.  
Cells exposed to the same environmental conditions (i.e. 37°C, 5%CO2) but 
normal pressure (0mmHg), served as a control for all experimentation. 
 
3.2.3.2 Cytokine Cocktail Stimulation 
Confluent HUVECs were stimulated with a cytokine/chemokine cocktail 
representing the serum levels of inflammatory mediators previously detected in our 
experimental model of CS (“CS cocktail”) (Donohoe 2015) (Table 3.1) for 6 hours. The 
CS cocktail contained human recombinant TNF-α (1ng/ml), IL-1β (100pg/ml) and GRO 
(1ng/ml). 
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3.2.4 Reactive Oxygen Species (ROS) Production 
The production of ROS in HUVECs was measured by intracellular oxidation of 
DHR-123, a pan-oxidant-sensitive fluorochrome, as previously described (Mizuguchi, 
Stephen et al. 2009). HUVECs (1x106 cells), grown to confluence in 12-well fibronectin-
coated plates, were loaded with DHR-123 (10µM) for 45min, and then subjected to either 
EHP of 30mmHg or stimulation with CS cytokine cocktail, for 6 hours, in the presence of 
CORM-3, or its inactive counterpart, iCORM-3. After stimulation, cells were washed 
with PBS, lysed in 0.5% CHAPS buffer and analysed spectrofluorometrically (FR-1501 
spectrofluorometer, Shimadzu) at excitation/emission wavelengths of 495/523nm. Protein 
concentration in the cell lysate was assessed by DC protein assay (BioRad, Mississauga, 
ON). ROS production was expressed as DHR-123 fluorescence intensity (FI) per mg 
protein. 
 
3.2.5 Measurement of the Endothelial Monolayer Integrity 
HUVECs were grown to confluence on fibronectin-coated transwell inserts (1µm 
diameter pores) (BD Falcon). Cells were subjected to 6 hours of either EHP of 30mmHg, 
or stimulation with CS cytokine cocktail, in the presence of CORM-3 (or iCORM-3). The 
integrity of the endothelial layer was assessed by measuring the transendothelial 
electrical resistance (TEER) using EndOhm chamber method (EndOhm-6, World 
Precision Instruments) following 1hr, 3hr and 6hr EHP or CS cytokine cocktail exposure, 
and expressed as Ωcm2. Changes in TEER from the baseline were evaluated at each time 
point. 
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Table 3.1 Serum levels of cytokines/chemokines detected in a rat model of CS. 
Twenty-four different cytokines and chemokines were tested; those with 
detectable values are shown here. Cytokines showing significant 
upregulation in response to CS were utilized to model CS in vitro. 
*p<0.05. 
 
Cytokine/Chemokine Baseline 
(pg/ml) 
CS 
(pg/ml) 
Fold 
change 
p-value 
Eotaxin 228.0±161.3 175.7±144.3 -0.2 0.4431 
TNF-a 33.7±6.8 1223.1±483.0* 36 0.0002 
IL-1a 473.9±291.7 434.7±179.3 -0.1 0.8887 
IL-1b 47.9±35.7 141.3±18.6* 3 0.0481 
MIP-1a 69.8 ±66.4 84.8±41.0 0.2 0.7012 
MCP-1 313.4±35.1 399.6±42.4 0.3 0.8737 
GRO/KC 990.2±213.3 2984±1310* 3 0.0194 
IFN-¡ 326.6±98.6 360.4±159.3 0.1 0.8463 
Leptin 9596±1038 8606±1353 -0.1 0.5344 
IL-6 2566±1758 2351±1494 -0.1 0.9084 
IL-13 225.3±60.0 254.9±106.9 0.1 0.7161 
IL-12p70 196.1±68.1 199.2±83.5 0 0.9718 
IL-18 86.6±7.3 76.4±6.1 -0.1 0.1621 
IP-10 145.4±108.6 155.7±108.9 0.1 0.9424 
RANTES 1673±250 1680±193 0 0.3560 
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3.2.6 Quantification of Apoptosis 
HUVECs grown on black fibronectin-coated 96-well plates with clear bottom 
(Greiner Bio-One) were subjected to either EHP of 30mmHg or stimulation with CS 
cytokine cocktail, for 6 hours, in the presence of CORM-3 (or iCORM-3). Levels of the 
activation of active caspases were assessed by FAM-FLICA poly caspase apoptosis kit 
(Immunochemistry Technologies, LLC), as per manufacturer’s instructions. Briefly, cells 
were incubated with FAM-FLICA poly caspase reagent for one hour at 37°C, washed and 
immediately assessed for fluorescence using Victor-3 plate reader (Perkin-Elmer), at 
excitation/emission wavelengths of 480nm/530nm. Levels of apoptosis were expressed as 
relative fluorescence units (RFU) (i.e. fluorescence intensity/104). 
 
3.2.7 PMN Rolling/Adhesion Assay 
HUVECs grown on the parallel-flow perfusion microslides (µ-slide VI0.4; ibidi, 
Madison, WI) were subjected to either EHP of 30mmHg or stimulation of with CS 
cytokine cocktail, for 6 hours, in the presence of CORM-3 (or iCORM-3). Following this, 
microslides with HUVECs were placed into an air-heated chamber (37°C) attached to an 
inverted phase-contrast microscope (Diaphot 300, Nikon). After 10min wash with M199 
in the presence of CORM-3 or iCORM-3 at a shear stress of 1dyn/cm2 obtained by 
syringe pump (Harvard Apparatus, St. Laurent, QC), PMNs (1x106/ml) isolated from 
healthy adult volunteers were added to the perfusion medium, and the perfusion was 
continued for 15 minutes at the same shear stress. PMN-HUVECs adhesive interactions 
(i.e. rolling, adhesion) were captured in six random fields of view (10s/field) with a 
digital CCD camera (Sony Corp., Japan) connected to a computer, and analyzed offline. 
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PMNs with velocity less than 100µm/s were considered “rolling”. Adhesion was defined 
as PMNs that remained stationary for at least 10s. PMN rolling/adhesion were expressed 
as a number of PMN/mm2. 
 
3.2.8 Statistical Analysis 
All parameters were expressed as means ± standard error of the mean (SEM), and 
analyzed using two-way analysis of variance (ANOVA) (GraphPad Prism, v. 5.0, San 
Diego, CA), with Bonferroni post-hoc test as needed. p<0.05 was considered statistically 
significant. All experiments were repeated four times (on 4 different days), to account for 
variability in ambient environmental factors. 
 
 
3.3 RESULTS 
3.3.1 ROS Production 
Exposure of HUVECs to EHP, or their incubation with CS cytokine cocktail 
induced a significant increase in the production of ROS, as shown in Figure 3.1. DHR-
123 fluorescence intensity increased from 578.0±43.4.5 FI/mg protein in unstimulated 
control cells to 791.5±64.4 and 1169.1±155.8 Fl/mg protein in cells exposed to EHP or 
CS cytokine cocktail, respectively (p<0.05). CORM-3 treatment significantly decreased 
ROS production in both the EHP and the CS cytokine cocktail groups, to 516.8±48.0 and 
468.3±37.8 Fl/mg protein, respectively (p<0.05), while it had no effect on the 
unstimulated control endothelial cells (Figure 3.1).  
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Figure 3.1 The effect of CORM-3 on the oxidative stress response in human 
vascular endothelial cells in an in vitro model of CS. HUVECs were 
subjected to 6 hours of sustained 30mmHg EHP or cytokine cocktail 
stimulation in the presence of CORM-3 (or iCORM-3), and the levels of 
ROS production were assessed by DHR-123 assay (two-way ANOVA, 
p<0.05, *p<0.05 from Control, †p<0.05 from EHP+iCORM-3 and 
Cytokine Cocktail+iCORM-3, N=4 per group).  
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3.3.2 Transendothelial Electrical Resistance (TEER) 
Exposure of HUVECs to EHP led to a gradual decrease in the integrity of the 
endothelial monolayer, as indicated by a decrease of TEER from the baseline of 
63.4±3.3Ωcm2 to 48.6.5±4.3Ωcm2, 38.7±3.2Ωcm2 and 35.3±3.5Ωcm2 at 1hr, 3hr and 6hr 
EHP, respectively (p<0.05). Incubation of HUVECs with cytokine cocktail produced a 
gradual decrease in TEER to 24.5±7.0Ωcm2, 16.1±7.1Ωcm2 and 13.6±6.2Ωcm2 at 1hr, 
3hr and 6hr exposure, respectively (p<0.05 from control) (Figure 3.2). 
CORM-3 treatment of cells exposed to EHP significantly diminished the 
magnitude of changes in TEER to 52.0±5.0Ωcm2, 52.1±2.3Ωcm2 and 47.0±3.2Ωcm2 at 
1hr, 3hr and 6hr, respectively (p<0.05 from EHP+iCORM-3). In parallel, CORM-3 
treatment of cells stimulated with CS cytokine cocktail significantly diminished the 
magnitude of changes in TEER to 44.4±3.0Ωcm2, 44.2±4.4Ωcm2 and 39.5±8.7Ωcm2 at 
1hr, 3hr and 6hr, respectively (p<0.05 from CS cytokine cocktail+iCORM-3) (Figure 
3.2). 
	
3.3.3 Apoptosis 
Exposure of HUVECs to EHP, or incubation with the CS cytokine cocktail led to 
a significant increase in the activation of caspases, as shown in Figure 3.3. Apoptosis 
increased from 2.4±0.1 RFU in control to 8.8±0.4 RFU in EHP and 10.3±1.0 RFU in 
cytokine cocktail groups (p<0.05). CORM-3 treatment significantly decreased the 
activation of caspases to 4.0±0.4 RFU in cytokine cocktail group (p<0.05), while having 
no effect on caspases activity in EHP group (8.6±0.3 RFU, n.s.) (Figure 3.3). CORM-3 or 
iCORM-3 had no effect on the activity of caspases in control cells.   
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Figure 3.2 The effect of CORM-3 on the integrity of human vascular endothelial 
cell monolayer in an in vitro model of CS. HUVECs were subjected to 6 
hours of sustained 30mmHg EHP, or cytokine cocktail stimulation, in the 
presence of CORM-3 (or iCORM-3), and the integrity of monolayer was 
assessed by measuring the transendothelial electrical resistance (TEER) 
(two-way repeated measures ANOVA, p<0.05, *p<0.05 from Control, 
†p<0.05 from Cytokine Cocktail+iCORM-3, #p<0.05 from EHP+iCORM-
3, N=3 per group).  
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Figure 3.3. The effect of CORM-3 on the level of apoptosis in human vascular 
endothelial cells in an in vitro model of CS. HUVECs were subjected to 
6 hours of sustained 30mmHg EHP or cytokine cocktail stimulation in the 
presence of CORM-3 (or iCORM-3), and the levels of active caspases 
were assessed by FAM-FLICA (two-way ANOVA, p<0.05, *p<0.05 from 
Control, †p<0.05 from Cytokine Cocktail+iCORM-3, N=4 per group). 
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3.3.4 Leukocyte Activation 
Exposure of HUVECs to EHP resulted in a marked increase in PMN activation, 
from 0.4±0.3 rolling PMNs/0.1mm2 and 4.0±1.5 adherent PMNs/0.1mm2 in control to 
2.2±0.6 rolling PMNs/0.1mm2 and 12.8±1.8 adherent PMNs/0.1mm2 in EHP group 
(p<0.05) (Figure 3.4). Incubation of HUVECs with the CS cytokine cocktail resulted in a 
significant increase in PMN activation to 2.1±0.3 rolling PMNs/0.1mm2 and 21.0±4.5 
adherent PMNs/0.1mm2 (p<0.05) (Figure 3.4).  
CORM-3 treatment of HUVECs exposed to EHP did not have significant effect . 
with 1.5±0.5 rolling PMN/0.1mm2 and 8.0±1.5 adherent PMN/0.1mm2. CORM-3 
treatment of HUVECs exposed to CS cytokine cocktail resulted in a significant decrease 
in PMN activation to 0.5±0.1 rolling PMN/0.1mm2 and 4.4±0.7 adherent PMN/0.1mm2 
(p<0.05) (Figure 4.4). There was no difference in PMN rolling or adhesion in 
unstimulated control HUVECs between the CORM-3 and iCORM-3 groups. 
 
 
3.4 DISCUSSION 
CS is associated with significant morbidity and patient disability (Giannoudis, 
Nicolopoulos et al. 2002) and often poses a significant clinical challenge for the 
physician and surgical team. Currently, the gold standard for definitive management of 
CS is surgical fasciotomy, with few other proven adjuncts (Olson and Glasgow 2005). 
While some supportive therapies have shown limited success in animal models (Manjoo, 
Sanders et al. 2010, Lawendy, Bihari et al. 2014), their use is hindered by the lack of 
understanding the full underlying pathophysiological basis of CS.  
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Figure 3.4 The effect of CORM-3 on leukocyte (A) rolling and (B) adhesion in 
response to EHP, or cytokine cocktail stimulation of human vascular 
endothelial cells in an in vitro model of CS. HUVECs were subjected to 
6 hours of sustained 30mmHg EHP, or cytokine cocktail stimulation, in 
the presence of CORM-3 (or iCORM-3), followed by application of naïve 
PMNs, while being superfused at a constant rate of 1dyn/cm2 (two-way 
ANOVA, p<0.05, *p<0.05 from Control, †p<0.05 from Cytokine 
Cocktail+iCORM-3, N=4 per group).  
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CS is a complex pathophysiological process, leading to upregulation pro-
inflammatory phenotype, followed by subsequent interactions between vascular 
endothelial cells and activated leukocytes. This leads to impaired vascular cell integrity, 
increased vascular permeability and leukocyte extravasation, followed by the clinical 
appearance of edema (Sabido, Milazzo et al. 1994). The production of pro-inflammatory 
mediators, coupled with leukocyte accumulation within the affected organ, is one of the 
key features of CS. While leukocyte recruitment at the site of injury is a normal 
physiological response, the overwhelming recruitment of PMNs, with the subsequent 
release of cytotoxic ROS and proteolytic enzymes, further exacerbates the parenchymal 
damage already seen in CS. Activated leukocytes are known to impair surrounding cell 
viability (Toyokuni 1999), further contributing to the already existing tissue injury and 
dysfunction. 
 Recent findings indicate that exogenous application of CO has potent anti-
inflammatory effects (Motterlini and Otterbein 2010). However, inhalation of CO may 
lead to the formation of toxic levels of COHb (i.e. >10%), thus limiting its clinical use 
(Ryter, Alam et al. 2006, De Backer, Elinck et al. 2009). In order to address this, CO-
releasing molecules (CO-RMs) - transitional metal carbonyls that can release CO on 
demand - have been synthesized. CO-RMs allow for CO delivery to the tissues without 
the associated rise in COHb and offer various routes of administration (IV, IP, SC or 
tissue superfusion) (Motterlini, Mann et al. 2005). Multiple studies have shown beneficial 
anti-inflammatory effects of CO-RMs: ischemia/reperfusion injury (Katada, Bihari et al. 
2010), pulmonary hypertension (Zuckerbraun, Chin et al. 2006), organ transplant (Song, 
Kubo et al. 2003) and sepsis (Cepinskas, Katada et al. 2008). 
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Currently, there is a dearth of knowledge when it comes to understanding the role 
of CO-RMs on modulation of the response seen in CS, as well as the changes 
experienced at the cellular and molecular levels. Recently, we developed and tested a 
relevant experimental animal models of CS (Lawendy, Sanders et al. 2011, Bihari 2017). 
The studies found that CORM-3 had a significant therapeutic impact by reducing the 
inflammatory response and the resulting tissue injury, while preserving microvascular 
perfusion (Lawendy, Bihari et al. 2014, Bihari 2017). However, there are currently no 
human patient studies which have evaluated the role of elevated hydrostatic pressure, or 
the response to CORM-3 in CS. 
In the present study, we attempted to mimic the CS conditions in vitro, by 
utilizing human vascular endothelial cells and two clinically-relevant CS stimuli, in order 
to examine the relative contribution of physical changes associated with EHP or 
cytokine-induced inflammation to the pathophysiology of CS, as well as to determine 
how CORM-3 offers protection upon exposure to these stimuli. To our knowledge, this is 
the first studies to model CS in such manner in humans. 
Exposure of HUVECs to EHP resulted in a significant increase in intracellular 
production of ROS (Figure 3.1). This can most likely be linked to changes in the 
mitochondrial respiratory chain (Wang, Guerrero et al. 2015), and upregulation of 
downstream signalling molecules, which in turn, triggers inflammation (Toyokuni 1999). 
In addition, incubation of HUVECs with CS cytokine cocktail also resulted in a similar 
response; the data is consistent with prior research findings in CS and ischemia-
reperfusion injury (Zhang, Hu et al. 2005, Cavaillon and Annane 2006, Lawendy, Bihari 
et al. 2014, Lawendy, Bihari et al. 2016). Cell stimulation by cytokines is known to 
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induce oxidative stress, leading to compromise of the cellular membrane, intercellular 
junctions and internal protein structures (Sprague and Khalil 2009). Our previous 
findings indicate that EHP also leads to significant stress fiber formation, changes in in F-
actin and VE-cadherin expression, leading to a breakdown of endothelial barrier 
(Acevedo, Bowser et al. 1993, Tokuda, Miyazaki et al. 2009, Cao, Xia et al. 2015).  
Increased oxidative stress, through ROS-based signalling, also leads to alterations 
in endothelial cell cytoskeleton and adherence junctions (Corada, Liao et al. 2001). In 
addition, previous reports found that EHP leads to an upregulation of cytokine levels in 
various cell types, such as periodontal ligament cells, bladder smooth muscles cells, 
mesenchymal stem cells, human tumour cells and human chondrocytes (Yamamoto, Kita 
et al. 2006, Fioravanti, Moretti et al. 2007, Fucikova, Moserova et al. 2014, Becquart, 
Cruel et al. 2016, Liang, Xin et al. 2016). The effect occurs through the upregulation of 
various downstream transcription factors, resulting in increased expression of various 
chemokines and cytokines (De Martin, Hoeth et al. 2000). 
 In our experiments, application of CORM-3 (but not iCORM-3) was able to 
diminish ROS release in both the EHP and cytokine cocktail stimulation groups. It has 
been demonstrated that there is a significant cross-talk between ROS and various 
enzymes, such as matrix metalloproteinases (MMP) and cell surface membrane proteins 
(various integrins) (Svineng, Ravuri et al. 2008).  In addition, it has been shown that EHP 
is able to modulate various cellular pathways, including the induction of MMP (Inoue, 
Arai et al. 2015). Interestingly, previous studies found that exogenous application of CO, 
in the form of CORM-2, was able to diminish the induction of MMP expression and its 
downstream effects (Tsai, Lee et al. 2017). These reports further support the notion that 
	 113 
the protective effect of CORM-3 is likely mediated through its effects on downstream 
transcription factors, upregulated by both the direct effect of EHP and the presence of 
various inflammatory cytokines. 
Exposure of human endothelial cells to EHP or CS cytokine cocktail led to a 
significant breakdown of the endothelial barrier, evidenced by a decrease in trans-
endothelial electrical resistance (Figure 3.2). Previously, EHP has been found to lead to 
changes in endothelial cell morphology and diffusion barrier characteristics in multiple 
cell types (Acevedo, Bowser et al. 1993, Ohashi, Sugaya et al. 2007, Tokuda, Miyazaki et 
al. 2009, Cao, Xia et al. 2015). Cellular permeability and leukocyte extravasation are 
controlled by adhesive interactions between various endothelial cell surface proteins 
(Ley, Laudanna et al. 2007). EHP appears to not only have an effect on cell-cell 
junctions, but it also affects the upregulation of adhesion molecules that are involved in 
microvessel integrity, as demonstrated by a rapid decrease in TEER, correlated with a 
transient loss and/or redistribution of PECAM-1 (Sharma, Templin et al. 2013, 
Souvannakitti, Peerapen et al. 2016). CORM-3 treatment preserved endothelial 
monolayer integrity; a plausible explanation being that CORM-3 can modulate F-actin 
expression/distribution and various transcription pathways (particulary MAPK) (Inoue, 
Patterson et al. 2017). Another possibility is that CORM-3 may modulate  mitochondria-
based pathways. Previous reports have found EHP leads to mitochondrial fission and a 
reduction in cellular ATP (Ju, Liu et al. 2007); CORM-3 has been shown to uncouple 
mitochondrial respiration and activate phosphate carriers, enhancing mitochondrial 
phosphate uptake (Long, Salouage et al. 2014). Additionally, CORM-3 also appears to 
have a significant impact on membrane potential and permeability, through its effects on 
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the transmembrane movement of K+ and Na+, causing changes in cellular respiration and 
H+ pumping (Wilson, Jesse et al. 2013). 
Treatment of endothelial cells with EHP or CS cytokine cocktail resulted in a 
significant increase in caspase activation. Surprisingly, while CORM-3 treatment 
prevented apoptosis in the CS cytokine cocktail group, it had no effect on apoptosis 
levels in the cells exposed to EHP. Increased oxidative stress, through ROS-based 
signalling (Toyokuni 1999), plays an important role in caspase activation and eventual 
apoptosis (Elmore 2007). Multiple studies, both in vivo and in vitro, have demonstrated 
the anti-apoptotic effects of CO (Brouard, Otterbein et al. 2000, Petrache, Otterbein et al. 
2000, Bihari, Cepinskas et al. 2014, Lawendy, Bihari et al. 2014). In the clinical and 
experimental scenario, elevated intracompartmental pressure leads to a significant rise in 
the inflammatory cytokine TNF- α (Lawendy, Bihari et al. 2015, Lawendy, Bihari et al. 
2016, Bihari 2017) which is an important mediator of apoptosis via modulation of the 
expression of various proteolytic caspases (Seekamp, Warren et al. 1993, Roebuck, 
Carpenter et al. 1999, Ley 2008). Previously, treatment with CORM-3 has been shown to 
lead to a significant decrease in circulating TNF-α levels (Cepinskas, Katada et al. 2008, 
Lawendy, Bihari et al. 2014, Donohoe 2015, Bihari 2017). Heme oxygenase inhibitors 
have also been shown to lead to a significant decrease in TNF-α-induced apoptosis in an 
in vitro model of both mouse fibroblasts and endothelial cells (Petrache, Otterbein et al. 
2000). In our study, the lack of CORM-3 effect upon exposure of HUVECs to EHP could 
be due to a relatively high dose of CORM-3 delivered to the HUVECs, changing its 
relative effect. In several experimental models of disease and/or tissue injury such as 
ischemia-reperfusion and  lung transplantation, pre-treatment with low dose CO led to a 
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net anti-apoptotic effect (Ryter, Alam et al. 2006), although higher concentrations of CO 
produced pro-apoptotic effects (Piantadosi, Zhang et al. 1997). In addition, apoptotic 
effects of EHP have been shown to be time dependent (Hasel, Durr et al. 2005); it is 
plausible to assume that the lack of response to CORM-3 could have been due to time 
dependent changes in activated caspase levels. 
The exposure of endothelial cells to EHP or CS cytokine cocktail led to a 
significant increase in leukocyte adhesive interactions (Figure 3.4), which remains a key 
feature of leukocyte and/or vascular endothelial cell inflammatory activation (Butcher 
1991, Ley, Laudanna et al. 2007). The process is mediated by various cytokines, 
chemokines and cell surface proteins on the activated endothelial cells (Albelda, Muller 
et al. 1991). Changes in hydrostatic pressure are likely to directly cause alterations in the 
expression of adhesion molecules on the vascular endothelium (e.g. P-selectin, E-selectin, 
ICAM-1, VCAM-1), allowing them to interact with their ligands on the PMNs (e.g. L-
selectin, sialyl-LewisX, β2 integrins).  
CORM-3 treatment was able to inhibit both leukocyte adhesion and rolling 
(Figure 3.4) in the cytokine cocktail group, but the beneficial effects were not reproduced 
in the EHP group. Previously, the application of CORM-2 significantly reduced levels of 
vascular endothelial adhesion molecules such as E-selectin and ICAM-1 (Nizamutdinova, 
Kim et al. 2009, Katada, Bihari et al. 2010). A decrease in E-selectin and VCAM-1 
expression has also been shown by pre-treatment with CORM-3 in HUVECs (Song, 
Bergstrasser et al. 2009). These results however, have not been universally found, as 
other studies have failed to show the ability of CORM-3 to suppress vascular endothelial 
cell adhesion protein expression (Urquhart, Rosignoli et al. 2007). Perhaps the lack of 
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statistically significant response in the EHP group following exposure to CORM-3 may 
be explained by its relative abilities to modulate adhesion on the endothelium when 
compared to the activated leukocytes. Although the effects of CORM-3 have been shown 
to modulate adhesive interactions on both activated leukocytes and the endothelium, its 
effect may be more significant on the former (Urquhart, Rosignoli et al. 2007). 
To our knowledge, this is the first study demonstrating the beneficial effects of 
carbon monoxide, delivered in the form of CORM-3, in two clinically relevant human in 
vitro models of CS. While the exact mechanisms of CORM-3 protective action remain to 
be determined, the obtained data helps translate previous animal model research to 
human trials, and suggests a potential therapeutic application of CORM-3 in CS. 
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CHAPTER 4. GENERAL DISCUSSION AND CONCLUSIONS 
 
 
4.1 OVERVIEW OF RESULTS 
CS is a true medical and surgical emergency associated with potentially 
devastating complications. Currently, the only proven treatment is surgical fasciotomy, to 
decompress all involved osseofascial compartments. The procedure, however, is 
associated with relatively frequent and significant complications leading to patient 
morbidity and dysfunction (Whitesides, Hirada et al. 1977). Certain adjunct and 
supportive therapies have shown limited therapeutic potential in various animal models 
(Manjoo, Sanders et al. 2010, Lawendy, Bihari et al. 2014, Bihari 2017), but their use in a 
clinical setting is hindered by our current lack of understanding of the underlying 
pathophysiology of CS, as well as their method of action. Recent reports utilizing animal 
models of CS have shown that unlike complete ischemia, CS creates a microcirculatory 
“low flow” environment, occurring in the presence of patent arterial vessels. This leads to 
early significant leukocyte activation, which in turn further contributes to parenchymal 
injury, cellular ischemia and limb dysfunction (Lawendy, Sanders et al. 2011). 
CO has emerged as an important mediator of cell signalling while also possessing 
anti-ischemic, anti-oxidant, anti-inflammatory, anti-apoptotic and vasodilatory properties 
(Kim, Ryter et al. 2006). In order to clinically utilize the beneficial attributes of this gas, a 
novel class of transition metal carbonyls capable of releasing CO on demand, the carbon 
monoxide-releasing molecules (CO-RMs), was experimentally synthesized (Motterlini, 
Clark et al. 2002). CO-RMs are capable of delivering safe levels of CO to the tissues in a 
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controlled manner, without causing a corresponding dangerous rise in COHb (Motterlini, 
Clark et al. 2002).  
Recent studies using animal models of CS (rat and pig) found that the 
administration of CORM-3 at the time of fasciotomy was associated with a decrease in 
leukocyte activation, systemic TNF-α release and diminished tissue injury, while 
improving microvascular perfusion (Lawendy, Bihari et al. 2014, Bihari 2017), but it has 
never been tested in human patients. In vitro modelling of CS allows to not only explore 
the underlying pathophysiology in a mechanistic manner, but also permits the 
development and testing of interventions (e.g. CO-RMs) that are currently not possible 
(or unethical) in humans. The goal of this thesis was to develop and test a relevant in 
vitro model of CS, using human cells, in order to expand our understanding of CS 
pathophysiology, as well as the development a safe medical adjunct (or standalone 
therapy) for patients presenting with CS. 
 
4.1.1 EHP As an In Vitro Model Of CS  
In Chapter 2, an attempt was made to mimic the CS conditions in vitro by 
subjecting human vascular endothelial cells (HUVECs) to the CS-relevant stimulus, in 
the form of elevated hydrostatic pressure (EHP), directly assessing cellular response, 
while attempting to clarify the role that EHP contributes to the endothelial activation and 
pro-inflammatory potential of CS. We found that exposure of HUVECs to EHP led to a 
rearrangement of endothelial monolayer, characterized by  significant stress fiber 
formation, as evidenced by changes in F-actin and VE-cadherin expression. Cells 
exposed to EHP also experienced a significant increase in intracellular production of 
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ROS, most likely due, at least in part, to changes in the mitochondrial respiratory chain 
and the inner mitochondrial membrane. It can also be surmised that this increase in ROS 
would then go on to trigger downstream signalling molecules, further stimulating 
inflammation (Toyokuni 1999). 
EHP applied to endothelial cells also led to a significant increase in leukocyte 
adhesion, a key feature of leukocyte and/or vascular endothelial cell inflammatory 
activation (Butcher 1991, Ley, Laudanna et al. 2007). These results suggest that EHP not 
only induces ROS production and apoptosis, but it also directly promotes endothelial cell 
activation. Changes in hydrostatic pressure most likely influence the transcription and 
expression of adhesion molecules on the vascular endothelium (e.g. P-selectin, E-selectin, 
ICAM-1, VCAM-1), which then allows the endothelium to interact with their ligands on 
the PMNs (e.g. L-selectin, sialyl-LewisX, β2 integrins), leading to increased endothelial 
permeability, extravasation, and in vivo, tissue edema and parenchymal injury. Thus, our 
study demonstrated that direct physical effects caused by elevated hydrostatic pressure 
within the injured limb also significantly contribute to the pathophysiology of CS. 
 
4.1.2 Effect of CORM-3  
In Chapter 3, we attempted to build on our results, by testing the effect of CORM-
3 on HUVECs exposed to elevated hydrostatic pressure, and compare the findings to the 
results obtained by CS cytokine cocktail stimulation. We studied the effects of CORM-3 
on ROS production, endothelial monolayer integrity, apoptosis and endothelial activation 
(leukocyte adhesion/rolling).  
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Application of CORM-3 was able to decrease intracellular ROS production in 
both the EHP and cytokine cocktail groups. In addition, CORM-3 also prevented the 
hydrostatic pressure-induced decrease in endothelial monolayer integrity, most likely by 
modifying EHP-induced cytoskeletal changes in F-actin or VE-cadherin. Surprisingly, 
while CORM-3 prevented apoptosis in the CS cytokine cocktail group, it had no effect on 
the level of apoptosis in the cells exposed to EHP, despite multiple studies previously 
demonstrating the anti-apoptotic effects of CO (Brouard, Otterbein et al. 2000, Petrache, 
Otterbein et al. 2000, Bihari, Cepinskas et al. 2014, Lawendy, Bihari et al. 2014). 
Both EHP and CS cytokine cocktail stimulation led to a significant endothelial 
activation, as demonstrated by an increase in leukocyte rolling and adhesion to the 
endothelial monolayer. CORM-3 treatment was able to inhibit this response in the CS 
cytokine cocktail group but did not have a similar effect in the hydrostatic pressure 
group. The difference in magnitude could be explained by the ability of CORM-3 to 
modulate the expression of various adhesion molecules on both activated leukocytes and 
the endothelium, with the effect being more significant on the former (Urquhart, 
Rosignoli et al. 2007). 
 
 
4.2 LIMITATIONS AND FUTURE DIRECTIONS  
Although we were able to demonstrate detrimental consequences of elevated 
hydrostatic pressure on endothelial cells, and the beneficial effects of CORM-3 in this 
novel in vitro human CS model, there were several limitations to these studies. We 
arbitrarily chose to expose HUVECs to a hydrostatic pressure of 30mmHg, as this level is 
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clinically relevant and feasible in the laboratory setting using a gravity-fed system. 
However, the ideal pressure to which HUVECs should be exposed to in order to mimic 
CS most effectively, has yet to be discerned. In addition, we did not expose endothelial 
cells to different pressure changes, which (presumably) could have led to a graded 
cellular response. Furthermore, we chose 4 to 6 hours of EHP based on previous reports 
and clinical relevancy; in the future, comparing longer or shorter periods of exposure may 
reveal interesting results in terms of cellular response and the effects of CORM-3.  
Another limitation is the fact that we used only one concentration of CORM-3, 
which we based on previous related reports. However, different concentrations may 
prove to be more effective, without compromising cell survival.  Although the goal of 
this specific model was to test the effect of elevated hydrostatic pressure on HUVEC and 
the potentially protective effect of CORM-3, other compounds with anti-oxidant and anti-
inflammatory properties, such as taurine, N-acetyl cysteine and vitamin C could 
potentially be utilized, individually or in combination.  
CORM-3 is in the early experimental stage, yet its effect on CS in various animal 
models has been significant. Although the purpose of our experimental design was to 
examine the effect of CORM-3 on CS specifically, in the future, CORM-3 could be tested 
in other conditions, such as Charcot changes in the diabetic foot. Charcot changes and 
ulceration have been associated with ischemia/reperfusion, elevated cytokine levels, 
reactive oxygen species, apoptosis and significant inflammatory changes (Folestad, 
Alund et al. 2015, Petrova, Petrov et al. 2015); A condition which appears to share many 
similarities with ischemia reperfusion and CS models and which may also respond 
favourably to CORM-3 treatment. 
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4.3 CONCLUSIONS 
The data in this thesis indicates that the effects of elevated hydrostatic pressure on 
endothelial cells is not inconsequential, and changes in hydrostatic pressure itself 
significantly contribute to the pathophysiology of CS. We demonstrated the beneficial 
effects of CORM-3 in an in vitro model of CS. Although certain outcomes were 
unexpected, such as the lack of the effect on caspase activation in response to CORM-3 
in EHP, our results suggest CORM-3 may be of benefit to patients suffering with CS. 
While the exact mechanisms of CORM-3 action remain to be elucidated, CORM-3 may 
have a significant potential as a pharmacological treatment to supplement and/or replace 
fasciotomy, thus avoid the devastating complications associated with CS. 
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